

## PRODUCT MONOGRAPH

**PrBREO<sup>®</sup> ELLIPTA<sup>®</sup>**

fluticasone furoate/vilanterol (as trifenate) dry powder for oral inhalation  
100 mcg/25 mcg  
200 mcg/25 mcg

Inhaled Corticosteroid (ICS) and Bronchodilator  
(Long-Acting Beta<sub>2</sub>-Adrenergic Agonist (LABA)) Combination

GlaxoSmithKline Inc.  
7333 Mississauga Road  
Mississauga, Ontario  
L5N 6L4

Date of Revision:  
January 27, 2016

Submission Control No: 188217

©2016 GlaxoSmithKline Inc. All Rights Reserved  
BREO and ELLIPTA are registered trade-marks of Glaxo Group Limited, used under license by GlaxoSmithKline Inc.

## **TABLE OF CONTENTS**

	<b>PAGE</b>
PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION.....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS.....	4
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS.....	13
DRUG INTERACTIONS.....	19
DOSAGE AND ADMINISTRATION.....	22
OVERDOSAGE.....	25
ACTION AND CLINICAL PHARMACOLOGY.....	26
STORAGE AND STABILITY.....	36
SPECIAL HANDLING INSTRUCTIONS.....	36
DOSAGE FORMS, COMPOSITION AND PACKAGING.....	36
 PART II: SCIENTIFIC INFORMATION.....	 37
PHARMACEUTICAL INFORMATION.....	37
CLINICAL TRIALS.....	38
DETAILED PHARMACOLOGY.....	52
TOXICOLOGY.....	54
REFERENCES.....	61
 PART III: CONSUMER INFORMATION.....	 62

# PrBreo<sup>®</sup> Ellipta<sup>®</sup>

fluticasone furoate/vilanterol dry powder for oral inhalation

## PART I: HEALTH PROFESSIONAL INFORMATION

### SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form/Strength	Nonmedicinal Ingredients
Oral Inhalation	Dry powder for oral inhalation/ 100 and 200 mcg fluticasone furoate/ 25 mcg vilanterol	Lactose monohydrate (which contains milk protein) and magnesium stearate

### INDICATIONS AND CLINICAL USE

#### COPD

Breo<sup>®</sup> Ellipta<sup>®</sup> (fluticasone furoate/vilanterol) 100/25 mcg is indicated for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations.

Fluticasone furoate is an inhaled corticosteroid (ICS) and vilanterol is a long-acting beta<sub>2</sub>-adrenergic agonist (LABA).

Breo<sup>®</sup> Ellipta<sup>®</sup> 100/25 mcg once daily is the only strength indicated for the treatment of COPD. Breo<sup>®</sup> Ellipta<sup>®</sup> 200/25 mcg is not indicated for patients with COPD. There is no additional benefit of the 200/25 mcg dose compared to the 100/25 mcg dose and there is a potential increased risk of pneumonia and systemic corticosteroid-related adverse reactions.

Breo<sup>®</sup> Ellipta<sup>®</sup> is **not** indicated for the relief of acute bronchospasm (see WARNINGS AND PRECAUTIONS, General).

## **Asthma**

BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg and BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg are indicated for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease.

BREO<sup>®</sup> ELLIPTA<sup>®</sup> is **not** indicated for patients whose asthma can be managed by occasional use of a rapid onset, short duration, inhaled beta<sub>2</sub>-agonist or for patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of a rapid onset, short duration, inhaled beta<sub>2</sub>-agonist.

LABAs, such as vilanterol, one of the active ingredients in BREO<sup>®</sup> ELLIPTA<sup>®</sup>, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients (see WARNINGS AND PRECAUTIONS). Therefore, when treating patients with asthma, physicians should only prescribe BREO<sup>®</sup> ELLIPTA<sup>®</sup> for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and do not use BREO<sup>®</sup> ELLIPTA<sup>®</sup> for patients whose asthma can be adequately controlled on low or medium dose inhaled corticosteroids.

BREO<sup>®</sup> ELLIPTA<sup>®</sup> is **not** indicated for the relief of acute bronchospasm (see WARNINGS AND PRECAUTIONS, General).

## **Geriatrics:**

No dosage adjustment is required in patients 65 years of age and older.

## **Pediatrics:**

The safety and efficacy in pediatric patients younger than 18 years have not been established.

## **CONTRAINDICATIONS**

- Patients who are hypersensitive to fluticasone furoate, vilanterol, or any ingredient in the formulation or component of the container (see DOSAGE FORMS, COMPOSITION AND PACKAGING).
- Patients with severe hypersensitivity to milk proteins (see WARNINGS AND PRECAUTIONS, Hypersensitivity).
- In the primary treatment of status asthmaticus or other acute episodes of asthma.

## WARNINGS AND PRECAUTIONS

### **ASTHMA-RELATED DEATH**

Long-acting beta<sub>2</sub>-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in BREO<sup>®</sup> ELLIPTA<sup>®</sup>, increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of salmeterol (SEREVENT<sup>®</sup> Inhalation Aerosol) or placebo added to patients' usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13,176 patients treated for 28 weeks on salmeterol versus 3 deaths out of 13,179 patients on placebo). Currently available clinical data are inadequate to determine whether concurrent use of inhaled corticosteroids mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients.

When treating asthma, physicians should therefore only prescribe BREO<sup>®</sup> ELLIPTA<sup>®</sup> for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and do not use BREO<sup>®</sup> ELLIPTA<sup>®</sup> for patients whose asthma can be adequately controlled on low or medium dose inhaled corticosteroids (see DOSAGE AND ADMINISTRATION, Dosing Considerations).

### **General**

#### ***Not for Acute Use***

It is crucial to inform patients that BREO<sup>®</sup> ELLIPTA<sup>®</sup> should not be used for the relief of acute symptoms of asthma or COPD (i.e., as rescue therapy for the treatment of acute episodes of bronchospasm). Patients should be prescribed a rapid onset, short duration inhaled bronchodilator (e.g., salbutamol) to relieve acute symptoms such as shortness of breath, and advised to have this available for use at all times.

When beginning treatment with BREO<sup>®</sup> ELLIPTA<sup>®</sup>, patients who have been taking a rapid onset, short duration, inhaled bronchodilator on a regular basis (e.g., q.i.d.) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief if they develop acute symptoms while taking BREO<sup>®</sup> ELLIPTA<sup>®</sup>.

#### ***Deterioration of Disease and Acute Episodes***

BREO<sup>®</sup> ELLIPTA<sup>®</sup> should not be initiated in patients with acutely deteriorating COPD or asthma, which may be a life-threatening condition. The use of BREO<sup>®</sup> ELLIPTA<sup>®</sup> in this setting is inappropriate.

COPD or asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient's inhaled, short-acting bronchodilator becomes less effective or the patient needs more inhalation of a short-acting bronchodilator than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the treatment regimen should be undertaken at once. Increasing the daily dosage of BREO<sup>®</sup> ELLIPTA<sup>®</sup> beyond the recommended dose is not appropriate in this situation.

Asthma-related adverse events and asthma or COPD exacerbations may occur during treatment with BREO<sup>®</sup> ELLIPTA<sup>®</sup>. Patients should be advised to continue treatment and seek medical advice if symptoms remain uncontrolled or worsen after initiation of therapy with BREO<sup>®</sup> ELLIPTA<sup>®</sup>.

Patients should not stop therapy with BREO<sup>®</sup> ELLIPTA<sup>®</sup>, in asthma or COPD, without physician supervision since symptoms may recur after discontinuation.

#### ***Excessive Use and Use with Other LABA Products***

BREO<sup>®</sup> ELLIPTA<sup>®</sup> should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using BREO<sup>®</sup> ELLIPTA<sup>®</sup> should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, indacaterol, olodaterol) for any reason.

#### **Carcinogenesis and Mutagenesis**

Animal data only (see TOXICOLOGY section).

#### **Cardiovascular**

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Cardiovascular effects such as tachycardia, arrhythmia, palpitations, myocardial ischemia, angina pectoris, hypertension or hypotension have been associated with use of beta-adrenergic agonists. In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. Like all products containing sympathomimetic agents, BREO<sup>®</sup> ELLIPTA<sup>®</sup> should therefore be used with caution in patients with severe cardiovascular disease, especially coronary insufficiency, cardiac arrhythmias (including tachyarrhythmias), or hypertension.

#### ***Hemodynamics***

Like other beta<sub>2</sub>-agonists, vilanterol can produce clinically significant cardiovascular effects in some patients as measured by an increase in pulse rate, systolic or diastolic blood pressure, or cardiac arrhythmias such as supraventricular tachycardia and extrasystoles. If such effects occur, BREO<sup>®</sup> ELLIPTA<sup>®</sup> may need to be discontinued.

BREO<sup>®</sup> ELLIPTA<sup>®</sup> was associated with a dose dependent increase in heart rate in healthy subjects receiving steady state treatment (see ACTION AND CLINICAL PHARMACOLOGY, Electrocardiography & Hemodynamics).

### ***Electrocardiography***

Caution is recommended if BREO<sup>®</sup> ELLIPTA<sup>®</sup> is administered to patients with a known history of QTc prolongation, risk factors for torsade de pointes (e.g., hypokalemia), or patients who are taking medications known to prolong the QTc interval (see DRUG INTERACTIONS, Drugs known to prolong the QTc interval). At a dose of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg, the largest mean difference from placebo in the QTcF interval was <5 ms at steady-state.

In healthy subjects receiving steady-state treatment of up to 4 times the recommended dose of vilanterol (representing a 10- or 12-fold higher systemic exposure than seen in patients with asthma or COPD, respectively) inhaled fluticasone furoate/vilanterol was associated with dose-dependent QTcF prolongation (see ACTION AND CLINICAL PHARMACOLOGY, Electrocardiography & Hemodynamics).

### **Ear/Nose/Throat**

Localized infections of the mouth and pharynx with *Candida albicans*, which are associated with the use of inhaled glucocorticosteroids, have occurred in patients treated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> during clinical studies. Patients should therefore be advised to rinse their mouth with water (without swallowing) after inhalation of BREO<sup>®</sup> ELLIPTA<sup>®</sup> to reduce the risk of oropharyngeal candidiasis.

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with BREO<sup>®</sup> ELLIPTA<sup>®</sup> continues. However, at times therapy with BREO<sup>®</sup> ELLIPTA<sup>®</sup> may need to be interrupted for the treatment of severe infections (see DRUG INTERACTIONS, Drug-Drug Interactions).

### **Endocrine and Metabolism**

Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur with inhaled corticosteroids than with oral corticosteroids. Possible systemic effects of BREO<sup>®</sup> ELLIPTA<sup>®</sup> include: Cushing's syndrome, Cushingoid features, hypothalamic-pituitary-adrenal (HPA) axis suppression, growth retardation in children and adolescents (in asthma) and a decrease in bone mineral density (BMD).

### ***Hypercorticism and Adrenal Suppression***

Inhaled fluticasone furoate is absorbed into the circulation and can be systemically active (see ACTION & CLINICAL PHARMACOLOGY, Pharmacodynamics). Exceeding the recommended dosage or co-administration with a strong cytochrome P450 3A4 (CYP3A4) inhibitor may result in HPA dysfunction (see DRUG INTERACTIONS, Drug-Drug Interactions).

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects. In light of the possibility of systemic absorption of inhaled corticosteroids, patients treated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response. If such effects occur, BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids, and other treatments for management of asthma or COPD symptoms should be considered.

### ***Systemic Steroid Replacement by Inhaled Steroid***

Particular care is needed for patients who have been transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of HPA function.

Patients who have been previously maintained on 20 mg or more of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although BREO<sup>®</sup> ELLIPTA<sup>®</sup> may control asthma or COPD symptoms during these episodes, in recommended doses it supplies less than normal physiological amount of glucocorticoid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies.

During periods of stress, a severe asthma attack, or a severe COPD exacerbation, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids immediately and to contact their physicians for further instruction. These patients should also be instructed to carry a warning card indicating that they may need supplementary systemic corticosteroids during periods of stress, a severe asthma attack, or severe COPD exacerbation.

Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to BREO<sup>®</sup> ELLIPTA<sup>®</sup>. Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with BREO<sup>®</sup> ELLIPTA<sup>®</sup>. Lung function (mean forced expiratory volume in 1 second [FEV<sub>1</sub>]), beta-agonist use, and asthma or COPD symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to BREO<sup>®</sup> ELLIPTA<sup>®</sup> may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy (e.g., rhinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions).



During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression), despite maintenance or even improvement of respiratory function.

### ***Reduction in Bone Mineral Density***

Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids (see ADVERSE REACTIONS, Fractures).

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. Since patients with COPD often have multiple risk factors for reduced BMD, assessment of BMD is recommended prior to initiating BREO<sup>®</sup> ELLIPTA<sup>®</sup> and periodically thereafter. If significant reductions in BMD are seen and BREO<sup>®</sup> ELLIPTA<sup>®</sup> is still considered medically important for that patient's COPD therapy, use of medication to treat or prevent osteoporosis should be strongly considered.

### ***Effect on Growth***

Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to children and adolescents (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Pediatrics).

### ***Hypokalemia and Hyperglycemia***

Beta-adrenergic agonist medications may produce significant hypokalemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation.

Beta-agonist medications may also produce transient hyperglycemia in some patients (see ACTION & CLINICAL PHARMACOLOGY, pharmacodynamics).

### ***Co-existing Conditions***

BREO<sup>®</sup> ELLIPTA<sup>®</sup>, like all medications containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the rapid onset, short-duration, beta<sub>2</sub>-adrenoceptor agonist salbutamol, when administered intravenously, have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis.

## **Hematologic**

### ***Eosinophilic Conditions***

In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions, with some patients presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition that is often treated with systemic corticosteroid therapy. These events usually, but not always, have been associated with the reduction and/or withdrawal of oral corticosteroid therapy following the introduction of inhaled corticosteroids. Physicians should be alerted to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal relationship between inhaled corticosteroids and these underlying conditions has not been established.

## **Hypersensitivity**

### ***Immediate Hypersensitivity Reactions***

Immediate hypersensitivity reactions have occurred after administration of BREO<sup>®</sup> ELLIPTA<sup>®</sup> (see ADVERSE REACTIONS, Post-Market Adverse Drug Reactions). If signs suggesting allergic reactions (in particular, difficulties in breathing or swallowing, swelling of tongue, lips and face, urticaria, skin rash) occur, BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be discontinued immediately and alternative therapy instituted. The patient should NOT be re-challenged with BREO<sup>®</sup> ELLIPTA<sup>®</sup> if this is identified as the cause of the hypersensitivity reaction (see CONTRAINDICATIONS).

There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of other powder products containing lactose; therefore, patients with severe milk protein allergy should not use BREO<sup>®</sup> ELLIPTA<sup>®</sup> (see CONTRAINDICATIONS).

## **Immune**

Patients who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible patients using corticosteroids. In such patients who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. If a patient is exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If a patient is exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. If chickenpox develops, treatment with antiviral agents may be considered.

For COPD patients, it is important that even mild chest infections be treated immediately since these patients may be more susceptible to damaging lung infections than healthy individuals. Patients should be instructed to contact their physician as soon as possible if they suspect an infection.

Physicians should recommend that COPD patients receive an annual influenza vaccination.

As with all medications containing a corticosteroid, BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be administered with caution, and only if necessary, in patients with active or quiescent tuberculosis infections of the respiratory tract; chronic or untreated infections such as systemic fungal, bacterial, viral, or parasitic; or ocular herpes simplex.

### **Ophthalmologic**

Glaucoma, increased intraocular pressure, and cataracts have been reported in patients following the long-term administration of inhaled corticosteroids. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.

### **Respiratory**

#### ***Paradoxical Bronchospasm***

As with other inhalation therapies, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with a rapid onset, short duration inhaled bronchodilator such as salbutamol. BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be discontinued immediately, the patient assessed, and alternative therapy instituted, if necessary.

#### ***Pneumonia***

**COPD:** An increase in the incidence of pneumonia has been observed in patients with COPD receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup>. There was also an increased incidence of pneumonias resulting in hospitalization. In some incidences these pneumonia events were fatal (see ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions, Pneumonia).

Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. Risk factors for pneumonia in patients with COPD receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup> include current smokers, patients with a history of prior pneumonia, patients with a body mass index <25 kg/m<sup>2</sup> and patients with an FEV<sub>1</sub> <50% predicted. These factors should be considered when BREO<sup>®</sup> ELLIPTA<sup>®</sup> is prescribed and treatment should be re-evaluated if pneumonia occurs.

**Asthma:** The incidence of pneumonia in patients with asthma was uncommon. Patients with asthma taking BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg may be at an increased risk of pneumonia compared with those receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg or placebo. No risk factors were identified.

### **Special Populations**

**Pregnant Women:** There are no adequate and well-controlled studies with BREO<sup>®</sup> ELLIPTA<sup>®</sup> in pregnant women. Corticosteroids and beta<sub>2</sub>-agonists have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Because animal studies are not always predictive of human response, BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be used during pregnancy only if the potential benefit

justifies the potential risk to the fetus. Women should be advised to contact their physician if they become pregnant while taking BREO<sup>®</sup> ELLIPTA<sup>®</sup>.

***Use in Labour and Delivery:*** There are no adequate and well-controlled human studies that have investigated the effects of BREO<sup>®</sup> ELLIPTA<sup>®</sup> during labour and delivery. Because beta-agonists may potentially interfere with uterine contractility, BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be used during labour only if the potential benefit justifies the potential risk.

***Nursing Women:*** It is not known whether fluticasone furoate or vilanterol are excreted in human breast milk. However, other corticosteroids and beta<sub>2</sub>-agonists have been detected in human milk. A risk to breastfed newborns/infants cannot be excluded. Since there are no data from controlled trials on the use of BREO<sup>®</sup> ELLIPTA<sup>®</sup> by nursing mothers, the use of BREO<sup>®</sup> ELLIPTA<sup>®</sup> by breast-feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant.

***Pediatrics:*** The safety and efficacy in pediatric patients younger than 18 years have not been established.

***Geriatrics:*** Based on the available data, there is no need to adjust the dose in elderly patients, but greater sensitivity of some older individuals cannot be ruled out.

***Hepatic Insufficiency:*** Fluticasone furoate systemic exposure increased by up to 3-fold in subjects with mild, moderate and severe hepatic impairment. Patients should be monitored for corticosteroid-related systemic effects. For patients with moderate to severe hepatic impairment, the 100/25 mcg dose should be used (see DOSAGE AND ADMINISTRATION and ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Hepatic Insufficiency).

### **Monitoring and Laboratory Tests**

Potentially serious hypokalemia has been observed with other beta-agonist therapies, which may increase susceptibility to cardiac arrhythmias. It is therefore recommended that serum potassium levels be monitored in patients predisposed to low levels of serum potassium.

Due to the hyperglycemic effect observed with other beta-agonists, additional blood glucose monitoring is recommended in diabetic patients.

For patients at risk, monitoring of bone and ocular effects (cataract and glaucoma) should also be considered in patients receiving maintenance therapy with BREO<sup>®</sup> ELLIPTA<sup>®</sup>.

Patients with hepatic impairment should be monitored for corticosteroid effects due to potentially increased systemic exposure of fluticasone furoate.

## ADVERSE REACTIONS

### Adverse Drug Reaction Overview

LABAs such as vilanterol, one of the active ingredients in BREO<sup>®</sup> ELLIPTA<sup>®</sup>, increase the risk of asthma-related death (see BOXED WARNING and WARNING AND PRECAUTIONS).

Data from COPD and asthma clinical trials were used to determine the frequency of adverse reactions associated with fluticasone furoate/vilanterol.

With the exception of pneumonia and fractures, the safety profile was similar in patients with asthma and COPD. During clinical studies, pneumonia and fractures were more frequently observed in patients with COPD.

### Pneumonia

**COPD:** In the two 12-month studies in COPD, there was a higher incidence of pneumonia reported in subjects receiving fluticasone furoate doses of 50, 100 and 200 mcg in fixed combination with vilanterol 25 mcg (6-7%) than in those receiving vilanterol 25 mcg alone (3%). Chest x-rays were performed for the majority of subjects with reported pneumonia. Of the x-rays taken, at least one-half in each treatment group showed infiltrates compatible with pneumonia. Pneumonia was considered to be serious in 3% of subjects receiving the combination in any strength and in < 1% of subjects receiving vilanterol. There was fatal pneumonia in 1 subject receiving the BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg and in 7 subjects receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg (<1% for each treatment group) (see WARNINGS AND PRECAUTIONS, Respiratory).

**Asthma:** In an integrated analysis of 18 studies in asthma (10,322 patients), the incidence of pneumonia (adjusted for exposure due to the disparate durations and variable samples sizes in the different treatment groups) seen with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (8.5/1000 patient years) was similar to placebo (9.3/1000 patient years). There was a slightly higher incidence of pneumonia in BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg (18.3/1000 patient years) compared to BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg. Few of the pneumonia events led to hospitalization with either strength, and there were no observed differences in the incidence of serious events between the two treatment strengths.

## **Fractures**

**COPD:** An increase in the incidence of bone fracture has been observed in patients with COPD receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup>. In two replicate 12-month studies in a total of 3,255 patients with COPD, bone fractures were reported by 2% of patients receiving fluticasone furoate doses of 50, 100, or 200 mcg in fixed combination with vilanterol 25 mcg and in <1% of patients receiving vilanterol 25 mcg. The majority of the fractures were due to trauma. Fractures customarily associated with corticosteroid use (e.g., spinal compression/thoracolumbar vertebral fractures, hip and acetabular fractures) occurred in <1% of subjects in all treatment arms (see WARNINGS AND PRECAUTIONS, Endocrine and Metabolism).

**Asthma:** In an integrated analysis of 18 studies in asthma (10,322 patients), the incidence of fractures was <1% in both BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg and 200/25 mcg groups, and usually associated with trauma.

## **Clinical Trial Adverse Drug Reactions**

### **By Indication**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

## **COPD Studies**

### **6-Month Trials**

The incidence of adverse events associated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> in [Table 1](#) is based upon two placebo-controlled 6-month clinical studies of 2,257 COPD patients. A total of 410 patients (129 females and 281 males) with COPD were treated once daily with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg. Other treatments included the individual components, fluticasone furoate and vilanterol inhalation powder, combinations containing different doses of fluticasone furoate, or placebo.

**Table 1 Adverse Events With  $\geq 1\%$  Incidence with BREO<sup>®</sup> ELLIPTA<sup>®</sup> Studies HZC112206 and HZC112207**

Adverse Event	BREO <sup>®</sup> ELLIPTA <sup>®</sup> 100/25 mcg  (n=410) n (%)	Vilanterol 25 mcg  (n=408) n (%)	Fluticasone Furoate 100 mcg  (n=410) n (%)	Placebo   (n=412) n (%)
<b>Infections and Infestations</b>				
Nasopharyngitis	35 (9)	41 (10)	32 (8)	31 (8)
Upper respiratory tract infection	29 (7)	20 (5)	16 (4)	13 (3)
Oropharyngeal candidiasis <sup>a</sup>	22 (5)	9 (2)	13 (3)	9 (2)
Sinusitis	7 (2)	7 (2)	9 (2)	3 (<1)
Bronchitis	6 (1)	2 (<1)	6 (1)	3 (<1)
Pharyngitis	5 (1)	2 (<1)	2 (<1)	2 (<1)
<b>Nervous System Disorders</b>				
Headache	29 (7)	36 (9)	30 (7)	20 (5)
<b>Musculoskeletal and Connective Tissue Disorders</b>				
Back pain	10 (2)	10 (2)	6 (1)	10 (2)
<b>Respiratory, Thoracic and Mediastinal Disorders</b>				
COPD	9 (2)	11 (3)	2 (<1)	8 (2)
Cough	7 (2)	3 (<1)	5 (1)	8 (2)
<b>Gastrointestinal Disorders</b>				
Nausea	6 (1)	5 (1)	5 (1)	4 (<1)
<b>Cardiac Disorders</b>				
Ventricular extrasystoles	6 (1)	4 (<1)	3 (<1)	3 (<1)
<b>General Disorders and Administration Site Conditions</b>				
Pyrexia	6 (1)	5 (1)	3 (<1)	1 (<1)

<sup>a</sup> Includes terms oral candidiasis, oropharyngeal candidiasis, candidiasis, and oropharyngitis fungal.

### 12-Month Trials

In addition to the events shown in Table 1, the incidence of adverse events associated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> were assessed from two 12-month COPD studies that did not include placebo controls. From the 3,255 COPD patients in these studies, 806 patients were treated once daily with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg. Other treatments included the individual component vilanterol inhalation powder, and two combinations containing a different dose of fluticasone furoate. The adverse events occurring in  $\geq 1\%$  of the subjects treated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg from these studies but not reflected in Table 1 above due to the lack of a placebo control included:

**Infections and infestations:** pneumonia, influenza, urinary tract infection, rhinitis, lower respiratory infection, cellulitis, gastroenteritis, herpes zoster, cystitis, otitis media

**Respiratory, thoracic and mediastinal disorders:** oropharyngeal pain, dyspnoea, allergic rhinitis, nasal congestion, dysphonia, rhinorrhoea

**Musculoskeletal and connective tissue disorders:** arthralgia, pain in extremity, muscle spasms, musculoskeletal pain, myalgia, musculoskeletal chest pain

**Gastrointestinal disorders:** diarrhoea, constipation, abdominal pain upper, gastritis, vomiting

**Nervous system disorders:** dizziness

**General disorders and administration site conditions:** oedema peripheral, fatigue

**Injury, poisoning and procedural complications:** muscle strain

**Skin and subcutaneous tissue disorders:** eczema

**Vascular disorders:** hypertension

**Metabolism and nutrition disorders:** hyperglycaemia

**Psychiatric disorders:** insomnia, anxiety, depression

**Eye Disorders:** conjunctivitis

**Blood and lymphatic system disorders:** anaemia

**Immune system disorders:** hypersensitivity

### **Asthma Studies**

BREO<sup>®</sup> ELLIPTA<sup>®</sup> for the treatment of asthma was studied in 18 double-blind, parallel-group, controlled trials (11 with placebo) of 4 to 76 weeks' duration, which enrolled 9,969 subjects with asthma. BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg was studied in 2,369 subjects and BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg was studied in 956 subjects. While subjects aged 12 to 17 years were included in these trials, BREO<sup>®</sup> ELLIPTA<sup>®</sup> is not approved for use in this age group. The safety data described below are based on two 12-week efficacy trials, one 24-week efficacy trial, and one long-term trial.

Study HZA106827 was a 12-week trial that evaluated the efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg in adolescent and adult subjects with asthma compared with fluticasone furoate 100 mcg and placebo. The incidence of adverse events associated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> is shown in [Table 2](#).



**Table 2 Adverse Events with  $\geq 1\%$  Incidence and More Common with BREO<sup>®</sup> ELLIPTA<sup>®</sup> Than Placebo in Study HZA106827**

<b>Adverse Event</b>	<b>BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (n=201) n (%)</b>	<b>Fluticasone Furoate 100 mcg (n=205) n (%)</b>	<b>Placebo (n=203) n (%)</b>
<b>Infections and infestations</b>			
Nasopharyngitis	20 (10)	14 (7)	15 (7)
Oral candidiasis	4 (2)	2 (<1)	0
Upper respiratory tract infection	3 (1)	4 (2)	0
<b>Nervous system disorders</b>			
Headache	10 (5)	9 (4)	8 (4)
<b>Respiratory, thoracic, and mediastinal disorders</b>			
Dysphonia	5 (2)	3 (1)	0
Oropharyngeal pain	4 (2)	4 (2)	3 (1)
Epistaxis	3 (1)	0	0

Study HZA116863 was a 12-week trial that evaluated the efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg, BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg and fluticasone furoate 100 mcg in adolescent and adult subjects with asthma. The incidence of adverse events associated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> is shown in [Table 3](#).

**Table 3 Adverse Events with ≥ 1% Incidence in Any Treatment Group in Study HZA116863**

<b>Adverse Event</b>	<b>BREO® ELLIPTA® 200/25 mcg (n=346) n (%)</b>	<b>BREO® ELLIPTA® 100/25 mcg (n=346) n (%)</b>	<b>Fluticasone Furoate 100 mcg (n=347) n (%)</b>
<b>Infections and infestations</b>			
Nasopharyngitis	25 (7)	22 (6)	26 (7)
Influenza	9 (3)	10 (3)	4 (1)
Upper respiratory tract infection	7 (2)	8 (2)	12 (3)
Bronchitis	7 (2)	2 (<1)	6 (2)
Sinusitis	6 (2)	4 (1)	2 (<1)
Oral candidiasis	4 (1)	2 (<1)	1 (<1)
Respiratory tract infection	4 (1)	1 (<1)	2 (<1)
Pharyngitis	2 (<1)	4 (1)	5 (1)
<b>Nervous system disorders</b>			
Headache	29 (8)	29 (8)	32 (9)
<b>Respiratory, thoracic and mediastinal disorders</b>			
Oropharyngeal pain	7 (2)	6 (2)	4 (1)
Cough	4 (1)	7 (2)	6 (2)
Rhinitis allergic	4 (1)	3 (<1)	2 (<1)
Dysphonia	2 (<1)	5 (1)	3 (<1)
<b>Gastrointestinal disorders</b>			
Abdominal pain upper	4 (1)	2 (<1)	0
Diarrhea	3 (<1)	4 (1)	2 (<1)
Toothache	3 (<1)	4 (1)	2 (<1)
<b>Musculoskeletal and connective tissue disorders</b>			
Back pain	5 (1)	4 (1)	7 (2)
<b>General disorders and administration site conditions</b>			
Pyrexia	3 (<1)	4 (1)	2 (<1)
<b>Injury, poisoning and procedural complications</b>			
Muscle strain	4 (1)	2 (<1)	0

Study HZA106829 was a 24-week trial that evaluated the efficacy of BREO® ELLIPTA® 200/25 mcg once daily compared with fluticasone furoate 200 mcg once daily and fluticasone propionate 500 mcg twice daily in adolescent and adult subjects with asthma. In addition to events shown in Table 3, adverse events occurring in greater than or equal to 1% of the subjects treated with BREO® ELLIPTA® 200/25 mcg (n=197) included:

**Infections and infestations:** respiratory tract infection viral, oropharyngeal candidiasis, cystitis, laryngitis, tonsillitis, pharyngitis

**Respiratory, thoracic and mediastinal disorders:** respiratory disorder, rhinitis perennial, dysphonia

**Gastrointestinal disorders:** abdominal pain, nausea, dry mouth, diarrhea

**Musculoskeletal and connective tissue disorders:** bone pain, arthralgia, musculoskeletal chest pain

**General disorders and administration site conditions:** pyrexia

**Psychiatric disorders:** nervousness

**Skin and subcutaneous tissue Disorders:** pruritus

### **12-Month Trial**

Long-term safety data is based on a 12-month trial that included 503 adolescent and adult subjects with asthma. In addition to events shown above for studies HZA106827, HZA116863 and HZA106829, adverse events occurring in greater than or equal to 1% of the subjects treated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (n=201) or BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg (n=202) for 12 months included extrasystoles, rhinitis and myalgia.

### **Post-Market Adverse Drug Reactions**

The following relevant adverse reactions have been identified from post-approval use of BREO<sup>®</sup> ELLIPTA<sup>®</sup>. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Cardiac Disorders:** palpitations, tachycardia

**Immune System Disorders:** hypersensitivity reactions including anaphylaxis, anaphylactic shock, angioedema, urticaria, pruritis, and skin rash.

**Musculoskeletal and Connective Tissue Disorders:** muscle spasms

**Nervous System Disorders:** tremor

**Psychiatric Disorders:** anxiety

## **DRUG INTERACTIONS**

### **Drug-Drug Interactions**

#### ***Drugs Known to Prolong the QTc Interval***

As with other beta<sub>2</sub>-adrenergic agonists, BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be administered with caution to patients treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QT interval, as any effect of these on the QT interval may be potentiated. Drugs known to prolong the QT-interval may increase the risk of ventricular arrhythmia (see WARNINGS AND PRECAUTIONS and ACTION AND CLINICAL PHARMACOLOGY).

### ***Sympathomimetic Agents***

Concomitant administration of other sympathomimetic agents (alone or as part of combination therapy) may potentiate the undesirable effects of BREO<sup>®</sup> ELLIPTA<sup>®</sup> (see WARNINGS AND PRECAUTIONS).

### ***Treatments Leading to Hypokalaemia***

Beta-agonists have been associated with reductions in serum potassium levels. Concomitant treatment with xanthine derivatives, oral corticosteroids (e.g. prednisone), or non-potassium sparing diuretics may potentiate any hypokalemic effect of adrenergic agonists (see WARNINGS AND PRECAUTIONS, Hypokalemia and Hyperglycemia).

### ***Beta-Adrenergic Blockers***

Beta-adrenergic blockers may weaken or antagonise the effect of BREO<sup>®</sup> ELLIPTA<sup>®</sup>. Therefore, BREO<sup>®</sup> ELLIPTA<sup>®</sup> should not be given together with beta-adrenergic blockers (including eye-drops) unless there are compelling reasons for their use. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

### ***Inhibitors of Cytochrome P450 3A4***

Fluticasone furoate and vilanterol are both substrates of CYP3A4. Co-administration of repeat dose ketoconazole (a strong CYP3A4 inhibitor and P-gp inhibitor) with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg resulted in increased mean fluticasone furoate AUC<sub>(0-24)</sub> and C<sub>max</sub> by 36% and 33%, respectively, and increased mean vilanterol AUC<sub>(0-t<sub>r</sub>)</sub> and C<sub>max</sub> by 65% and 22%, respectively. The increase in fluticasone furoate exposure was associated with a 27% reduction in weighted mean serum cortisol (0 to 24 hours). The increase in vilanterol exposure was not associated with an increase in beta-agonist-related systemic effects on heart rate or blood potassium but was associated with a slight increase in QTcF interval. Therefore, caution is required with the co-administration of BREO<sup>®</sup> ELLIPTA<sup>®</sup> and ketoconazole or other potent CYP3A4 inhibitors.

Administration of inhaled vilanterol 25 mcg alone with ketoconazole 400 mg resulted in a 1.9 fold increase in vilanterol systemic exposure as measured by AUC<sub>(0-t)</sub>, but there was no change in C<sub>max</sub>. The increase in AUC was not associated with effects on heart rate, blood potassium, and QTcF.

Fluticasone furoate and vilanterol are both substrates of P-glycoprotein (P-gp). Co-administration of repeat-dose verapamil, P-gp inhibitor, with vilanterol in combination with a long-acting muscarinic antagonist did not affect the pharmacokinetics of vilanterol. No P-gp inhibitor drug interaction studies have been conducted with fluticasone furoate alone or in combination with vilanterol.

**Table 4**      **Established or Potential Drug-Drug Interactions**

<b>Drug type</b>	<b>Ref</b>	<b>Effect</b>	<b>Clinical comment</b>
Inhibitors of cytochrome P450 3A4	CT	May inhibit the metabolism of, and increase the systemic exposure to, fluticasone furoate and vilanterol.	Caution should be exercised when considering the co-administration of BREO <sup>®</sup> ELLIPTA <sup>®</sup> with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin, indinavir, itraconazole, lopinavir, nelfinavir, saquinavir, voriconazole).
Inhibitors of P-glycoprotein (P-gp)	CT	May alter the systemic exposure to fluticasone furoate and/or vilanterol.	Verapamil did not affect the pharmacokinetics of vilanterol administered in combination with a long-acting muscarinic antagonist. Drug interaction studies with a specific P-gp inhibitor and fluticasone furoate (alone or in combination with vilanterol) have not been conducted.
Sympathomimetic agents	T	Potential pharmacodynamics interaction (additive pharmacologic and adverse effects)	Caution is recommended for concomitant use of BREO <sup>®</sup> ELLIPTA <sup>®</sup> and sympathomimetic agents administered by any route.
Beta-Adrenergic receptor blocking agents	T	Block pulmonary effect of beta-agonists, such as vilanterol, a component of BREO <sup>®</sup> ELLIPTA <sup>®</sup> .  May produce severe bronchospasm in patients with reversible obstructive airways disease.	Patients with asthma or COPD should not normally be treated with beta-blockers. However, under certain circumstances, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents for these patients; cardioselective beta-blockers could be considered, although they should be administered with caution.
Non-potassium sparing diuretics (i.e., loop or thiazide diuretics)	T	ECG changes and/or hypokalemia can be acutely worsened by beta-agonists, especially when the recommended dose of beta-agonists is exceeded.	Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.

<b>Drug type</b>	<b>Ref</b>	<b>Effect</b>	<b>Clinical comment</b>
Drugs that prolong the QTc interval  Monoamine Oxidase Inhibitors and Tricyclic Antidepressants	T	Cardiovascular system may be potentiated by these agents.  Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.	Vilanterol, like other beta <sub>2</sub> -agonists, should be administered with caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval.
Xanthine derivatives	T	Potential pharmacodynamic interaction (increased risk of hypokalemia)	Use with caution in conjunction with beta-agonists.
Acetylsalicylic acid	T		Use with caution in conjunction with corticosteroids in hypoprothrombinemia.

Legend: CT = Clinical Trial; T = Theoretical

### **Drug-Food Interactions**

Interactions with food have not been established. No clinically relevant effect of food would be expected and therefore a food interaction study was not conducted.

### **Drug-Herb Interactions**

Interactions with herbal products have not been established.

### **Drug-Laboratory Test Interactions**

Interactions with laboratory tests have not been established.

## **DOSAGE AND ADMINISTRATION**

### **Dosing Considerations**

LABAs, such as vilanterol, one of the active ingredients in BREO<sup>®</sup> ELLIPTA<sup>®</sup>, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients.

When treating patients with asthma, physicians should only therefore prescribe BREO<sup>®</sup> ELLIPTA<sup>®</sup> for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA.

Once asthma control is achieved and maintained, assess the patient at regular intervals and do not use BREO<sup>®</sup> ELLIPTA<sup>®</sup> for patients whose asthma can be adequately controlled on low or medium dose inhaled corticosteroids (see WARNINGS & PRECAUTIONS).

As with other inhaled drugs containing beta<sub>2</sub>-adrenergic agents, BREO<sup>®</sup> ELLIPTA<sup>®</sup> should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. When beginning treatment with BREO<sup>®</sup> ELLIPTA<sup>®</sup>, patients who have been taking rapid onset, short duration, inhaled beta<sub>2</sub>-agonists on a regular basis (e.g., q.i.d) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief if they develop acute respiratory symptoms while taking BREO<sup>®</sup> ELLIPTA<sup>®</sup>.

It is crucial to inform patients that BREO<sup>®</sup> ELLIPTA<sup>®</sup> should not be used to treat acute symptoms of asthma or COPD. Patients should be prescribed a rapid onset, short duration inhaled bronchodilator (e.g., salbutamol) to relieve the acute symptoms such as shortness of breath and advised to have this available for use at all times.

Patients with asthma should be regularly re-assessed by a healthcare professional so that the dose of BREO<sup>®</sup> ELLIPTA<sup>®</sup> they are receiving remains optimal and is only changed on medical advice. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.

Patients should be made aware that for optimum benefit, BREO<sup>®</sup> ELLIPTA<sup>®</sup> must be used regularly, even when asymptomatic.

If a previously effective dose of BREO<sup>®</sup> ELLIPTA<sup>®</sup> fails to provide adequate control of asthma symptoms, patients should seek medical advice as this indicates worsening of their underlying condition.

### **Recommended Dose and Dosage Adjustment**

The recommended dose of BREO<sup>®</sup> ELLIPTA<sup>®</sup> in adults 18 years of age and older is:

	<b>COPD</b>	<b>Asthma</b>
<b>BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg</b>	One inhalation once daily	One inhalation once daily
<b>BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg</b>	Not indicated	One inhalation once daily

## **COPD**

The recommended dose is one inhalation of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg once daily. The maximum recommended dose is one inhalation of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg once daily.

BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg is not indicated for the treatment of COPD.

## **Asthma**

The recommended dose is one inhalation of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg or 200/25 mcg once-daily. The maximum recommended dose is one inhalation of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg once daily.

The starting dose is based on patients' asthma severity. For patients previously treated with low- to mid-dose corticosteroid-containing treatment, BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg should be considered. For patients previously treated with mid- to high-dose corticosteroid-containing treatment, BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg should be considered.

For patients who do not respond adequately to one inhalation of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg once-daily, switching to one inhalation of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg once-daily may provide additional asthma control.

## **Administration**

BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be administered once-daily at the same time every day (morning or evening) by oral inhalation only. Do not use BREO<sup>®</sup> ELLIPTA<sup>®</sup> more than once every 24 hours. After inhalation, patients should rinse their mouth with water (without swallowing).

## **Dosing in Special Populations**

### **Geriatrics**

No dosage adjustment is required in patients 65 years of age and older (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics).

### **Renal Insufficiency**

No dose adjustment is required for patients with renal impairment (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Renal Insufficiency).



## **Hepatic Insufficiency**

Fluticasone furoate systemic exposure ( $C_{max}$  and AUC) increased by up to 3-fold in subjects with mild, moderate and severe hepatic impairment. Caution should be exercised when dosing patients with hepatic impairment as they may be more at risk of systemic adverse reactions associated with corticosteroids. Patients should be monitored for corticosteroid-related side effects. No dosage adjustment is required for patients with mild hepatic impairment. For patients with moderate or severe hepatic impairment, the maximum dose is 100/25 mcg (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Hepatic Insufficiency).

## **Missed Dose**

If a dose is missed, the patient should be instructed to take the next dose when it is due. The patient should be instructed not to take an extra dose.

## **OVERDOSAGE**

BREO<sup>®</sup> ELLIPTA<sup>®</sup> contains both fluticasone furoate and vilanterol. There is no specific treatment for an overdose with fluticasone furoate/vilanterol combination therapy. The risks associated with overdose for the individual components described below therefore apply to BREO<sup>®</sup> ELLIPTA<sup>®</sup>. Further management should be as clinically indicated or as recommended by regional Poison Control centres, where available.

### **Fluticasone Furoate**

Chronic overdosage (use at excessive doses for prolonged periods) may result in signs/symptoms of hypercorticism (see WARNINGS AND PRECAUTIONS).

The potential for acute toxic corticosteroid effects following overdosage with BREO<sup>®</sup> ELLIPTA<sup>®</sup> is low. Because of low systemic bioavailability (15.2%) and an absence of acute drug related systemic findings in clinical trials, overdosage of fluticasone furoate is unlikely to require any treatment other than observation.

Single- and repeat-dose trials of fluticasone furoate at doses of 50 to 4,000 mcg have shown fluticasone furoate to be well tolerated. Decreases in mean serum cortisol were observed at dosages of 500 mcg or higher given once daily for 14 days.

## Vilanterol

The expected signs and symptoms with overdosage of vilanterol are those typical of excessive beta-adrenergic stimulation (e.g., angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, QTc prolongation, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis). As with all inhaled sympathomimetic medicines, cardiac arrest and even death may be associated with an overdose of vilanterol.

In the event of drug overdose, discontinue BREO<sup>®</sup> ELLIPTA<sup>®</sup> and initiate appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta receptor blocker may be considered, bearing in mind that such medicine can produce bronchospasm. Cardiac monitoring including electrocardiogram monitoring is recommended in cases of overdosage.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

## ACTION AND CLINICAL PHARMACOLOGY

### Mechanism of Action

BREO<sup>®</sup> ELLIPTA<sup>®</sup> contains both fluticasone furoate (a synthetic corticosteroid) and vilanterol (a selective long-acting beta<sub>2</sub>-adrenergic agonist). Fluticasone furoate and vilanterol represent two distinct classes of medication having different effects on clinical and physiological indices.

Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate affects asthma and COPD symptoms is not known. Inflammation is an important component in the pathogenesis of asthma and COPD. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, basophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in *in vitro* and *in vivo* models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as NFκB resulting in inhibition of pro-inflammatory cytokines, and inhibition of antigen-induced lung eosinophilia in sensitized rats. These anti-inflammatory actions of corticosteroids may contribute to their efficacy.

Fluticasone furoate has been shown *in vitro* to exhibit a binding affinity for the human glucocorticoid receptor that is approximately 29.9 times that of dexamethasone and 1.7 times that of fluticasone propionate. *In vitro* studies have shown that translocation of the glucocorticoid receptor into the cell nucleus (essential for anti-inflammatory activity) is both more rapid and more prolonged with fluticasone furoate compared with fluticasone

propionate. Nuclear localization of the glucocorticoid receptor was observed at 30 hours post-exposure with fluticasone furoate but not with fluticasone propionate. The clinical relevance of these findings is unknown.

Vilanterol is a selective LABA, with bronchodilatory effects maintained for 24-hours. The pharmacologic effects of beta<sub>2</sub>-adrenoceptor agonist drugs, including vilanterol, are at least in part attributable to stimulation of intracellular adenylyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibit the release of mediators of immediate hypersensitivity from cells, especially mast cells. Although beta<sub>2</sub>-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta<sub>1</sub>-receptors are the predominant receptors in the heart, there are also beta<sub>2</sub>-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta<sub>2</sub>-agonists may have cardiac effects.

## **Pharmacodynamics**

### **Fluticasone furoate/vilanterol**

The median time to onset of action, defined as a 100-mL increase from baseline in FEV<sub>1</sub>, was 16 minutes in subjects receiving fluticasone furoate/vilanterol 100 mcg/25 mcg. After starting treatment, maximum benefit may not be achieved for at least 1 week or longer. Individual patients will experience a variable time to onset and degree of symptom relief.

There is no evidence of tachyphylaxis with respect to the direct pharmacological effect of BREO<sup>®</sup> ELLIPTA<sup>®</sup> on lung function.

### **Fluticasone furoate**

Effects on HPA-axis function are known to occur with systemic administration of corticosteroids and this systemic side effect has also been reported with inhaled and intranasal corticosteroid use (see DETAILED PHARMACOLOGY, Healthy Subjects).

Based on both clinical pharmacology and clinical data, inhaled fluticasone furoate at repeat doses up to 400 mcg was not consistently associated with statistically significant decreases in serum or urinary cortisol in healthy subjects. At higher doses, above the therapeutic range, corticosteroid class-related decreases in serum and urine cortisol levels were observed. In line with the increased fluticasone furoate systemic exposure, serum cortisol was reduced by approximately a third in subjects with moderate hepatic impairment after fluticasone furoate/vilanterol 200/25 mcg administration and a similar effect would be anticipated in subjects with severe hepatic impairment at this dose.

## **Vilanterol**

Class-related systemic effects that are known to occur with systemic administration of beta-agonists include hypokalaemia, hyperglycaemia, and increases in blood pressure, heart rate and the QTc interval. Following inhaled administration these effects are limited by local topical administration in the lung, low clinical doses and first pass metabolism of the swallowed portion of the dose and also tended to diminish on repeat dosing.


The clinical pharmacology data indicate that vilanterol 25 mcg is not associated with clinically significant class-related beta<sub>2</sub>-adrenoceptor systemic effects. Vilanterol, administered either alone or in combination with fluticasone furoate at doses up to 50 mcg was not associated with clinically relevant or statistically significant effects on blood potassium or blood glucose. Vilanterol 100 mcg was associated with a small decrease in blood potassium (approximately  $\leq 0.1$  mmol/L) and a small increase in blood glucose (approximately  $< 1$  mmol/L). Vilanterol at doses up to 100 mcg was not consistently associated with clinically relevant or statistically significant effects on blood pressure. Where PD effects were seen, there was no evidence of an increased effect with repeat dosing while some effects showed signs of diminishing.

### ***Electrocardiography and Hemodynamics***

The effect of fluticasone furoate/vilanterol on ECG parameters was investigated in 85 healthy subjects in a double-blind, randomised, placebo- and active- controlled, 4-way crossover study. Fluticasone furoate/vilanterol 200/25 mcg and fluticasone furoate/vilanterol 800/100 mcg were administered once daily for 7 days. The fluticasone furoate/vilanterol dose represented up to 4 times the recommended dose of vilanterol in fluticasone furoate/vilanterol, and a 10 or 12-fold higher vilanterol systemic exposure than seen in patients with asthma and COPD, respectively.

Increases in the QTcF interval were observed that were maximal at 30 min post-dosing. At the 30 min time point, the placebo-adjusted mean changes from baseline in the QTcF interval (ms) were 4.5 (90% CI 2.1, 6.9) in the fluticasone furoate/vilanterol 200/25 mcg treatment arm and 9.6 (90% CI 7.2, 12.0) in the fluticasone furoate/vilanterol 800/100 mcg treatment arm.


**Figure 1** QTcF Treatment Differences From Placebo: Adjusted Mean Change (and 90% CI) from Baseline by Time (0-24H) on Day 7 – All Subjects Population (FF/VI data only; manually read ECGs)



\*QTcF=QT/RR0.33

Increases in heart rate were observed that were maximal at 10 min. At the 10 min time point, the placebo-adjusted mean change from baseline in heart rate (bpm) was 7.6 (90% CI 6.3, 8.9) in the fluticasone furoate/vilanterol 200/25 mcg treatment arm and 17.0 (90% CI 15.7, 18.3) in the fluticasone furoate/vilanterol 800/100 mcg treatment arm.

**Figure 2 Heart Rate Differences From Placebo: Adjusted Mean Change (and 90% CI) from Baseline by Time (0-24H) on Day 7 – All Subjects Population (FF/VI data only; manually read ECGs)**



(See WARNINGS AND PRECAUTIONS, Cardiovascular; DRUG INTERACTIONS, Drugs that prolong the QTc interval, Non-potassium sparing diuretics (i.e., loop or thiazide diuretics) and Xanthine derivatives)

**Cardiovascular Effects in subject with COPD:** In 4 clinical studies of 6- and 12-month duration, there was no evidence of a treatment effect on heart rate, QTc(F), or blood pressure in subjects with COPD given combination doses of fluticasone furoate/vilanterol 50/25 mcg and BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg and 200/25 mcg, the individual components of fluticasone furoate or vilanterol alone, or placebo (see ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions).

**Cardiovascular Effects in subjects with Asthma:** In a clinical trial of 52-week duration, there was no evidence of a treatment effect on QTc(F) or blood pressure in subjects with asthma given BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg and 200/25 mcg once daily compared with fluticasone propionate 500 mcg twice daily. There was a 4- to 6-beats/min increase in heart rate observed 10 minutes after dosing with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg or BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg compared with fluticasone propionate 500 mcg twice daily. When heart rate was examined over a 0 to 24-hour period via Holter monitoring, the observed effect was smaller.

## Pharmacokinetics

**Table 5 Summary of Fluticasone Furoate and Vilanterol Pharmacokinetic Parameters in Healthy Subjects**

Fluticasone furoate/vilanterol 800/100 mcg	T <sub>max</sub> (h)	t <sub>1/2</sub> (h)
	Median (range)	Geometric Mean (CV%)
Fluticasone Furoate 800 mcg	1.00 (0.08, 3.00)	23.7 (22.6)
Vilanterol 100 mcg	0.17 (0.08, 0.25)	2.47 (84.0)

**Table 6 Summary of Fluticasone Furoate and Vilanterol (C<sub>max</sub> and AUC<sub>(0-24)</sub>) in Subjects with COPD (Geometric Mean [95% CI])**

BREO <sup>®</sup> ELLIPTA <sup>®</sup> 100/25 mcg	C <sub>max</sub> (pg/mL)	AUC <sub>(0-24)</sub> (pg.h/mL)
Fluticasone Furoate 100 mcg <sup>1</sup>	12.0 [10.9, 13.0]	182.2 [169.6, 194.7]
Vilanterol 25 mcg <sup>2</sup>	43.2 [41.8, 44.6]	265.7 [259.5, 271.9]

<sup>1</sup> Population pharmacokinetics analyses across 3 trials in subjects with COPD who received BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg.

<sup>2</sup> Population pharmacokinetics analyses across 4 trials in subjects with COPD who received BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg.

**Table 7 Summary of Fluticasone Furoate and Vilanterol (C<sub>max</sub> and AUC<sub>(0-24)</sub>) in Subjects with Asthma (Geometric Mean [95% CI])**

Population/Treatment	C <sub>max</sub> (pg/mL)	AUC <sub>(0-24)</sub> (pg.h/mL)
Fluticasone Furoate 100 mcg <sup>1</sup>	16.0 [15.6, 16.5]	244.3 [236.0, 252.5]
Fluticasone Furoate 200 mcg <sup>1</sup>	31.4 [30.3, 32.4]	495.3 [480.1, 510.6]
Vilanterol 25 mcg <sup>1</sup>	49.5 [46.6, 52.5]	168.7 [163.9, 173.5]

<sup>1</sup> Population pharmacokinetics analyses across 4 trials in subjects with asthma who received BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 or 200/25 mcg.

### **Absorption:**

**Fluticasone Furoate:** Fluticasone furoate acts locally in the lung; therefore, plasma levels do not predict therapeutic effect. Absolute bioavailability of fluticasone furoate after administration of fluticasone furoate/vilanterol 800/100 mcg was 15.2%. Systemic exposure for fluticasone furoate following inhaled administration is primarily due to absorption of the inhaled portion of the dose delivered to the lung since oral bioavailability from the swallowed portion of the dose is on average 1.26%.

**Vilanterol:** Vilanterol acts locally in the lung; therefore, plasma levels do not predict therapeutic effect. Absolute bioavailability of vilanterol after administration of fluticasone furoate/vilanterol 800/100 mcg was 27.3%. Systemic exposure for vilanterol following inhaled administration is primarily due to absorption of the inhaled portion of the dose delivered to the lung since oral bioavailability from the swallowed portion of the dose of vilanterol is <2%.

There was no difference in exposure to vilanterol between individual component and combination treatment.

### **Distribution:**

**Fluticasone Furoate:** Following intravenous administration to healthy subjects, the mean volume of distribution at steady state was 661 L. The binding of fluticasone furoate to human plasma proteins was high (99.6%).

**Vilanterol:** Following intravenous administration to healthy subjects, the mean volume of distribution at steady state was 165 L. Binding of vilanterol to human plasma proteins was 93.9%.

### **Metabolism:**

**Fluticasone Furoate:** Following intravenous administration to healthy subjects, fluticasone furoate was cleared from systemic circulation principally by hepatic metabolism via CYP3A4 (total plasma clearance of 65.4 L/hr). Fluticasone furoate undergoes fast first pass metabolism and is primarily metabolized through hydrolysis of the S-fluoromethyl carbothioate group to metabolites with significantly reduced corticosteroid activity. There was no in vivo evidence for cleavage of the furoate moiety resulting in the formation of fluticasone.

**Vilanterol:** Following intravenous administration, the pharmacokinetics of vilanterol showed a high plasma clearance of 108 L/hour. Following oral administration, vilanterol undergoes fast first pass metabolism and was mainly metabolized, principally via CYP3A4, by O-dealkylation to a range of metabolites with significantly reduced  $\beta_1$ - and  $\beta_2$ -agonist activity.

### **Elimination:**

**Fluticasone Furoate:** Fluticasone furoate and its metabolites are eliminated primarily in the feces, accounting for approximately 101% and 90% of the orally and intravenously administered dose, respectively. Urinary excretion accounted for approximately 1% and 2% of the orally and intravenously administered doses, respectively. Following repeat-dose inhaled administration, the plasma elimination phase half-life averaged 24 hours.



**Vilanterol:** Following oral administration, vilanterol was eliminated mainly by metabolism followed by excretion of metabolites in urine and feces (approximately 70% and 30% of the recovered radioactive dose, respectively). Following single-dose inhaled administration, the plasma elimination phase half-life averaged 2.5 hours. The plasma elimination half-life of vilanterol, as determined from inhalation administration of multiple doses of vilanterol 25 mcg, is 16.0 hours in subjects with asthma and 21.3 hours in subjects with COPD.

### **Special Populations and Conditions**

**Pediatrics:** The safety and efficacy of fluticasone furoate/vilanterol in patients younger than 18 years have not been established. Population pharmacokinetics analyses demonstrated no evidence of an age effect on the pharmacokinetics of fluticasone furoate or vilanterol in patients with asthma.

In a 24- to 76-week exacerbation trial, subjects received BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (n=1,009) or fluticasone furoate 100 mcg (n=1,010). Subjects had a mean age of 42 years and a history of one or more asthma exacerbations that required treatment with oral/systemic corticosteroids or emergency department visit or in-patient hospitalization for the treatment of asthma in the year prior to study entry. Adolescents aged 12 to 17 years made up 14% of the study population (n=281), with a mean exposure of 352 days for subjects in this age-group treated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (n=151) and 355 days for subjects in this age-group treated with fluticasone furoate 100 mcg (n=130). In this age-group, 10% of subjects treated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg reported an asthma exacerbation compared with 7% for subjects treated with fluticasone furoate 100 mcg. Among the adolescents, asthma-related hospitalizations occurred in 4 subjects (2.6%) treated with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared with 0 subjects treated with fluticasone furoate 100 mcg. There were no asthma-related deaths or asthma-related intubations observed in the adolescent age-group.

### **Effects on Growth**

Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to children and adolescents. A reduction of growth velocity in children and adolescents may occur as a result of poorly controlled asthma or from use of corticosteroids, including inhaled corticosteroids. The effects of long-term treatment of children and adolescents with inhaled corticosteroids, including fluticasone furoate, on final adult height are not known.

Controlled clinical trials have shown that inhaled corticosteroids may cause a reduction in growth in children. In these trials, the mean reduction in growth velocity was approximately 1 cm/year (range: 0.3 to 1.8 cm/year) and appears to be related to dose and duration of exposure. This effect has been observed in the absence of laboratory evidence of HPA axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in children than some commonly used tests of HPA axis function. The long-term effects of this reduction in growth velocity associated with orally inhaled corticosteroids, including the impact on final adult height, are unknown. The potential for “catch-up” growth following discontinuation of treatment with orally

inhaled corticosteroids has not been adequately studied. The growth of children and adolescents receiving orally inhaled corticosteroids, including BREO<sup>®</sup> ELLIPTA<sup>®</sup>, should be monitored routinely (e.g., via stadiometry). The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks associated with alternative therapies. To minimize the systemic effects of orally inhaled corticosteroids, including BREO<sup>®</sup> ELLIPTA<sup>®</sup>, each patient should be titrated to the lowest dose that effectively controls his/her symptoms.

A randomized, double-blind, parallel-group, multicenter, 1-year, placebo-controlled trial evaluated the effect of once-daily treatment with 110 mcg of fluticasone furoate in the nasal spray formulation on growth velocity assessed by stadiometry. The subjects were 474 pre-pubescent children (girls aged 5 to 7.5 years and boys aged 5 to 8.5 years). Mean growth velocity over the 52-week treatment period was lower in the patients receiving fluticasone furoate nasal spray (5.19 cm/year) compared with placebo (5.46 cm/year). The mean reduction in growth velocity was 0.27 cm/year (95% CI: 0.06 to 0.48) (see WARNINGS and PRECAUTIONS, Endocrine and Metabolism).

**Geriatrics:** The population pharmacokinetic analyses showed no clinically relevant influence of age on the pharmacokinetics of either fluticasone furoate or vilanterol in subjects with asthma or COPD.

Clinical studies of BREO<sup>®</sup> ELLIPTA<sup>®</sup> for COPD included 2,508 subjects aged 65 and older and 564 subjects aged 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Clinical studies of BREO<sup>®</sup> ELLIPTA<sup>®</sup> for asthma included 854 subjects aged 65 years and older. Trials did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects.

**Gender:** The population pharmacokinetic analyses showed no influence of gender on the pharmacokinetics of either fluticasone furoate or vilanterol in subjects with asthma or COPD.

**Race:** The systemic exposure ( $AUC_{(0-24)}$ ) to inhaled fluticasone furoate 200 mcg was 27% to 49% higher in East Asian healthy subjects of Japanese, Korean, and Chinese heritage compared with healthy Caucasian subjects. The higher fluticasone furoate systemic exposure corresponded with lower serum cortisol levels over 24 hours (22%) in Japanese subjects only when compared to Caucasian subjects. Similar differences were observed for East Asian subjects with COPD. In subjects with asthma, vilanterol  $C_{max}$  is estimated to be higher (3-fold) and  $AUC_{(0-24)}$  comparable for those subjects from an Asian heritage compared with subjects from a non-Asian heritage. However, the higher  $C_{max}$  values are similar to those seen in healthy subjects. In addition, in patients with asthma, these differences were not associated with any impact on markers of systemic effects, such as urine cortisol excretion and heart rate. As seen from clinical trials in subjects with Asian ancestry, there was also no evidence of increased risk of adverse events despite the higher exposure to FF and VI seen in this population.

**Hepatic Insufficiency:** The impact of hepatic impairment on the pharmacokinetics of combination doses of fluticasone furoate/vilanterol was evaluated in patients with mild (n=9), moderate (n=9) and severe (n=8) hepatic insufficiency, stratified using the Child-Pugh classification. Subjects with mild or moderate hepatic impairment and healthy control subjects (n=9) received fluticasone furoate/vilanterol 200/25 mcg once daily for 7 days. As a precaution, subjects with severe hepatic impairment received a lower combination dose of fluticasone furoate/vilanterol 100/12.5 mcg once daily for 7 days. For patients with moderate or severe hepatic impairment the maximum dose is 100/25 mcg (see DOSAGE AND ADMINISTRATION, Hepatic Insufficiency).

**Fluticasone Furoate:** There was an increase in fluticasone furoate systemic exposure (up to 3-fold increase in  $AUC_{(0-24)}$ ) in subjects with mild, moderate, or severe hepatic impairment compared with healthy subjects. In subjects with moderate hepatic impairment, mean serum cortisol (0 to 24 hours) was reduced by 34% compared with healthy subjects.

**Vilanterol:** Hepatic impairment had no effect on vilanterol systemic exposure.

**Renal Insufficiency:** Neither fluticasone furoate nor vilanterol systemic exposure was significantly greater in subjects with severe renal impairment (creatinine clearance <30 mL/min) compared with healthy subjects. The effects of hemodialysis have not been studied.

## STORAGE AND STABILITY

Do not store above 25°C. Store in a dry place away from direct heat or sunlight.

In use shelf-life is six weeks. BREO<sup>®</sup> ELLIPTA<sup>®</sup> should be safely discarded when the dose counter reads “0” or 6 weeks after it was removed from the foil tray, whichever comes first.

Keep out of sight and reach of children.

If you store in a refrigerator, allow the inhaler to return to room temperature for at least an hour before use.

## SPECIAL HANDLING INSTRUCTIONS

BREO<sup>®</sup> ELLIPTA<sup>®</sup> is provided in a foil laminate tray containing a desiccant packet and the tray is sealed with a peelable foil lid, which together with the desiccant provides moisture protection. The lid should only be opened when it is ready to be used for the first time. Once opened the desiccant package should be discarded.

## DOSAGE FORMS, COMPOSITION AND PACKAGING

BREO<sup>®</sup> ELLIPTA<sup>®</sup> consists of an inhaler device with a plastic light grey body, dose counter and a light blue mouthpiece cover. The inhaler device encompasses two double foil blister strips both having either 14 or 30 blisters each. On one strip, each blister contains a white dry powder mixture of micronized fluticasone furoate (100 or 200 mcg) and lactose monohydrate (12.5 mg) for inhalation administration. On the other strip, each blister contains a white dry powder mixture of micronized vilanterol trifenate (40 mcg equivalent to 25 mcg of vilanterol), magnesium stearate (125 mcg), and lactose monohydrate (12.5 mg) for inhalation administration. The lactose monohydrate contains milk proteins.

***BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg:*** Each single inhalation dispenses 100 micrograms of fluticasone furoate and 25 micrograms vilanterol (as trifenate). Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 92 micrograms of fluticasone furoate and 22 micrograms of vilanterol (as trifenate).

***BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg:*** Each single inhalation dispenses 200 micrograms of fluticasone furoate and 25 micrograms vilanterol (as trifenate). Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 184 micrograms of fluticasone furoate and 22 micrograms of vilanterol (as trifenate).

The actual amount of drug delivered to the lung will depend on patient factors, such as inspiratory flow rate and inspiratory time.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper name: fluticasone furoate

Chemical name: (6 $\alpha$ ,11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ )-6,9-difluoro-17-[[[(fluoromethyl)thio]carbonyl]-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate

Molecular formula and molecular mass: C<sub>27</sub>H<sub>29</sub>F<sub>3</sub>O<sub>6</sub>S 538.6

Structural formula:




Physicochemical properties: fluticasone furoate is a white powder. It is practically insoluble in water.

Proper name: vilanterol trifenate

Chemical name: triphenylacetic acid-4-{(1R)-2-[(6-{2-[2,6-dichlorobenzyl]oxy}ethoxy)hexyl]amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1)

Molecular formula and molecular mass: C<sub>24</sub>H<sub>33</sub>Cl<sub>2</sub>NO<sub>5</sub>.C<sub>20</sub>H<sub>16</sub>O<sub>2</sub> 774.8

Structural formula:



Physicochemical properties: vilanterol is a white powder. It is practically insoluble in water.

## CLINICAL TRIALS

### **Clinical Studies in COPD**

The efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> was evaluated in four clinical studies in patients with a clinical diagnosis of COPD (see [Table 8](#)).

Two 6-month randomized controlled studies (HZC112206, HZC112207; Lung Function Studies) were designed to evaluate the efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> in improving lung function (weighted Mean FEV<sub>1</sub> 0-4 hours post dose and pre-dose trough FEV<sub>1</sub>) in patients with COPD.

Two one-year randomized controlled studies (HZC102970, HZC102871; Exacerbation Studies) were designed to evaluate the efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> in reducing exacerbations of COPD (defined as worsening symptoms that required treatment with oral corticosteroids and/or antibiotics or in-patient hospitalization) in COPD patients with a history of exacerbations.

The detail of the design and patient demographics for these studies is described in [Table 8](#).

**Table 8 Summary of Patient Demographics for Clinical Studies in COPD**

Study #	Trial Design Dosage, route of administration and duration	Study Subjects (n=number)	Mean age (Range)	Gender n (%)
HZC112206	24 week treatment, multicenter, randomized, placebo-controlled, double-blind, parallel group study to evaluate the efficacy and safety of once-daily FF/VI 50/25 mcg, FF/VI 100/25 mcg, FF 100 mcg, VI 25 mcg, and placebo in subjects with COPD.	Total: 1030 FF/VI 50/25 mcg: 206 FF/VI 100/25 mcg: 206 FF 100 mcg: 206 VI 25 mcg: 205 Placebo: 207	63 years (40-85)	Male: 685 (67)  Female: 345 (33)
HZC112207	24 week treatment, multicenter, randomized, placebo-controlled, double-blind, parallel group study to evaluate the efficacy and safety of once-daily FF/VI 100/25 mcg, FF/VI 200/25 mcg, FF 100 mcg, FF 200 mcg, VI 25 mcg, and placebo in subjects with COPD.	Total: 1224 FF/VI 100/25 mcg: 204 FF/VI 200/25 mcg: 205 FF 100 mcg: 204 FF 200 mcg: 203 VI 25 mcg: 203 Placebo: 205	62 years (40-85)	Male: 885 (72)  Female: 339 (28)
HZC102970	52 week treatment, multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of once-daily FF/VI 50/25 mcg, 100/25 mcg and 200/25 mcg versus VI 25 mcg on the annual rate of moderate and severe exacerbations in subjects with COPD with a history of exacerbations.	Total: 1633 FF/VI 50/25 mcg: 412 FF/VI 100/25 mcg: 403 FF/VI 200/25 mcg: 409 VI 25 mcg: 409	64 years (40-88)	Male: 906 (55)  Female: 727 (45)
HZC102871	52 week treatment, multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of once-daily FF/VI 50/25 mcg, 100/25 mcg and 200/25 mcg versus VI 25 mcg on the annual rate of moderate and severe exacerbations in subjects with COPD with a history of exacerbations.	Total: 1622 FF/VI 50/25 mcg: 408 FF/VI 100/25 mcg: 403 FF/VI 200/25 mcg: 402 VI 25 mcg: 409	64 years (40-90)	Male: 964 (59)  Female: 658 (41)

**Notes:**

FF: fluticasone furoate

VI: vilanterol

***Lung Function Studies***

HZC112206 and HZC112207 were 24 week randomized, double-blind, placebo controlled, parallel group studies comparing the effect of BREO<sup>®</sup> ELLIPTA<sup>®</sup> to vilanterol 25 mcg and fluticasone furoate alone, and placebo. Of the 2,254 randomized patients who received at least one treatment dose, the majority were male (70%) and Caucasian (84%), and ranged in age from 40 to 85 years (mean age: 62 years). At screening, the mean post-bronchodilator percent predicted FEV<sub>1</sub> was 48.1% (range: 14-87%), and the mean percent reversibility was 13.8% (range -41%, 152%). The mean smoking history was 44.1 pack years, and 54% of the patients were current smokers.


HZC112206 evaluated the efficacy of fluticasone furoate/ vilanterol 50/25 mcg (n=206) and BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (n=206) compared with fluticasone furoate 100 mcg (n=206), vilanterol 25 mcg (n=205) and placebo (n=207), all administered once daily.

HZC112207 evaluated the efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (n=204) and BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg (n=205) compared with fluticasone furoate 100 mcg (n=204) and 200 mcg (n=203) and vilanterol 25 mcg (n=203) and placebo (n=205), all administered once daily.

The co-primary endpoints in both studies were the weighted mean FEV<sub>1</sub> from 0 to 4 hours post-dose at Day 168 and change from baseline in pre-dose trough FEV<sub>1</sub> at the end of the study.

In HZC112206, BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg increased the weighted mean FEV<sub>1</sub> (0-4 hours) relative to placebo by 173 mL by the end of the 24 week treatment period (Figure 3). Similarly, an increase of 214 mL was observed in HZC112207 (data not shown). In addition, patients receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg had a greater increase in weighted mean FEV<sub>1</sub> (0-4 hours) compared with those receiving fluticasone furoate 100 mcg (difference of 120 and 168 mL in Studies HZC112206 and HZC112207, respectively), demonstrating the contribution of vilanterol to the improvement in lung function with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg.

**Figure 3 HZC112206: Weighted Mean FEV<sub>1</sub> (0-4 hours) (L)**




**Notes:**

FF: fluticasone furoate  
 VI: vilanterol



The second co-primary variable, change from baseline in trough FEV<sub>1</sub> following the final treatment day, was increased by 115 mL in Study HZC112206 (Figure 4) and by 144 mL in Study HZC112207 compared with placebo (data not shown). Improvement in trough FEV<sub>1</sub> with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared with vilanterol 25 mcg (45 to 48 mL) did not achieve statistical significance.

**Figure 4 HZC112206: Change From Baseline in Trough FEV<sub>1</sub> (L)**



**Notes:**

FF: fluticasone furoate

VI: vilanterol

**Exacerbation Studies**

Studies HZC102970 and HZC102871 were 52 week randomized, double-blind, parallel-group, studies comparing the effect of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg, BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg, fluticasone furoate/ vilanterol 50/25 mcg and vilanterol 25 mcg, all administered once daily, on the annual rate of moderate/severe exacerbations in subjects with COPD with a smoking history of at least 10 pack years, a post-salbutamol FEV<sub>1</sub>/FVC ratio ≤0.70, post-salbutamol FEV<sub>1</sub> ≤70% predicted and documented history of ≥ 1 COPD exacerbation that required antibiotics and/or oral corticosteroids or hospitalization in the 12 months prior to visit 1.

The intent to treat population included 3,255 patients with an established history of COPD and a history of exacerbations (but no other significant respiratory disorders) and a smoking history of a mean of 46.2 pack years. A majority of the patients were male (57%) and Caucasian (85%), and ranged in age from 40 to 90 (mean age: 64 years). At screening, the mean post-bronchodilator FEV<sub>1</sub> was 1.29 L (range: 0.32 to 3.48L), the mean post-bronchodilator percent predicted FEV<sub>1</sub> was 45.4% (range: 12% to 91%), and mean post-bronchodilator FEV<sub>1</sub>/FVC ratio of 45.5% (range: 17% to 81%) indicated that the patient population had moderate to very severe airflow obstruction. The mean percent reversibility was 14.5% (range: -65% to 313%).

The primary endpoint was the annual rate of moderate and severe exacerbations. Moderate/severe exacerbations were defined as worsening symptoms that required treatment with oral corticosteroids and/or antibiotics or in-patient hospitalization. Both studies had a 4 week run-in period during which all subjects received open-label fluticasone propionate/salmeterol 250/50 mcg twice daily to standardize COPD pharmacotherapy and stabilize disease prior to randomization to blinded study medication for 52 weeks. Prior to run-in, subjects discontinued use of previous COPD medications except rescue short-acting bronchodilators. The use of concurrent inhaled long-acting bronchodilators (beta<sub>2</sub>-agonist and anticholinergic), ipratropium/salbutamol combination products, oral beta<sub>2</sub>-agonists, and theophylline preparations were not allowed during the treatment period. Oral corticosteroids and antibiotics were allowed for the acute treatment of COPD exacerbations with specific guidelines for use. Subjects used salbutamol on an as-needed basis throughout the studies.

The results of both studies showed that treatment with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg once daily resulted in a lower annual rate of moderate/severe COPD exacerbations compared with vilanterol (Table 9).

**Table 9 Analysis of Exacerbation Rates Following 12 months of Treatment**

Endpoint	HZC102970		HZC102871	
	VI (n=409)	FF/VI 100/25 mcg (n=403)	VI (n=409)	FF/VI 100/25 mcg (n=403)
Adjusted mean Annual rate	1.14	0.90	1.05	0.70
Ratio vs. VI 95% CI		0.79 (0.64, 0.97)		0.66 (0.54, 0.81)

**Notes:**

FF: fluticasone furoate

VI: vilanterol

In the HZC102970 study, BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg significantly lowered the risk for time to first moderate or severe exacerbation at any time point compared to treatment with vilanterol 25 mcg alone (hazard ratio of 0.8 [95% CI: 0.66, 0.99]). In the HZC102871 study, the risk for time to first moderate or severe exacerbation at any time point was numerically lower for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared to vilanterol 25 mcg alone (hazard ratio of 0.72 [95% CI: 0.59, 0.89]).

In the HZC102970 study, BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg significantly reduced the annual rate of COPD exacerbations requiring systemic/oral corticosteroids compared to treatment with vilanterol 25 mcg alone (ratio of 0.77 [95% CI (0.60, 0.99)]). In the HZC102871 study, the annual rate of COPD exacerbations requiring systemic/oral corticosteroids was numerically lower for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared to vilanterol 25 mcg alone (ratio of 0.62 [95% CI (0.49, 0.78)]).

### **Clinical Studies in Asthma**

The efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> was evaluated in 4 randomized, double-blind, parallel-group clinical trials in adolescent and adult subjects aged 12 years and older with asthma (see [Table 10](#)).

Three trials were designed to evaluate the safety and efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> given once daily in the evening in subjects who were not controlled on their current treatments of inhaled corticosteroids or combination therapy consisting of an inhaled corticosteroid plus a LABA. A 24- to 76 week trial was designed to evaluate the efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared with FF 100 mcg in reducing asthma exacerbations, as measured by time to first asthma exacerbation. This trial enrolled subjects who had had one or more asthma exacerbations in the year prior to trial entry.

Study treatments were delivered as inhalation powders.

While subjects aged 12 to 17 years were included in these trials, BREO<sup>®</sup> ELLIPTA<sup>®</sup> is not approved for use in this age group.

The detail of the design and patient demographics for these asthma studies is described in [Table 10](#).

**Table 10 Summary of Patient Demographics for Clinical Studies in Asthma**

Study #	Trial Design Dosage, route of administration and duration	Study Subjects (n=number)	Age Range	Gender n (%)
HZA106827	12 week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of FF/VI 100/25 mcg and FF 100 mcg both administered once-daily in the evening in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma.	Total: 609 FF/VI 100/25 mcg: 201 FF 100 mcg: 205 Placebo: 203	12-84	Male: 256 (42)  Female: 353 (58)
HZA116863	12 week treatment, multicenter, randomized, double-blind, parallel group, study to compare the efficacy and safety of FF/VI 200/25 mcg inhalation powder, FF/VI 100/25 mcg inhalation powder, and FF 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents	Total: 1,039 FF/VI 100/25 mcg: 346 FF/VI 200/25 mcg: 346 FF 100 mcg: 347	12-82	Male: 411 (40)  Female: 628 (60)
HZA106829	24 week treatment, multicenter, randomized, double-blind, parallel group study to compare the efficacy and safety of FF/VI 200/25 mcg administered once-daily each evening with FF 200 mcg administered once-daily each evening and FP 500 mcg administered twice daily in adolescent and adult subjects 12 years of age and older with persistent asthma.	Total: 586 FF/VI 200/25 mcg: 197 FF 200 mcg: 194 FP 500 mcg: 195	12-76	Male: 241 (41)  Female: 345 (59)
HZA106837	24-76 week treatment, multicenter, randomized, double-blind, parallel group study to evaluate the efficacy of FF/VI 100/25 mcg in reducing severe asthma exacerbations as measured by time to first severe asthma exacerbation when compared with FF 100 mcg alone. Both drugs were administered once-daily in the evening in subjects 12 years of age and older with asthma who had had one or more asthma exacerbation in the year prior to trial entry.	Total: 2,019 FF/VI 100/25 mcg: 1009 FF 100 mcg: 1010	12-82	Male: 669 (33)  Female: 1350 (67)

**Notes:**

FF/VI: BREO<sup>®</sup> ELLIPTA<sup>®</sup>

FF: fluticasone furoate

FP: fluticasone propionate

VI: vilanterol

In trials HZA106827 and HZA106829, change from baseline in weighted mean FEV<sub>1</sub> (0 to 24 hours) and change from baseline in trough FEV<sub>1</sub> at approximately 24 hours after the last dose at study endpoint (12 and 24 weeks, respectively) were co-primary efficacy endpoints. In trial HZA106829, change from baseline in percentage of rescue-free 24-hour periods over the 24-week treatment period was a powered secondary endpoint. Change from baseline in percentage of 24-hour periods without asthma symptoms was a secondary endpoint.

In trial HZA116863, change from baseline in weighted mean FEV<sub>1</sub> (0 to 24 hours) at Week 12 was the primary efficacy endpoint; change from baseline in trough FEV<sub>1</sub> at approximately 24 hours after the last dose at Week 12, and change from baseline in percentage of rescue-free 24-hour periods over the 12-week treatment period were powered secondary endpoints. Change from baseline in percentage of 24-hour periods without asthma symptoms was also a secondary endpoint.

Weighted mean FEV<sub>1</sub> (0 to 24 hours) was derived from serial measurements taken within 30 minutes prior to dosing and postdose assessments at 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours after the final dose.

### ***HZA106827***

HZA106827 was a 12-week trial that evaluated the efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg in subjects with asthma compared with fluticasone furoate 100 mcg and placebo. Subjects receiving low- to mid-dose inhaled corticosteroid (fluticasone propionate 100 to 250 mcg twice daily or equivalent) or low-dose inhaled corticosteroid plus a LABA (fluticasone propionate/salmeterol 100 mcg/50 mcg twice daily or equivalent) entered a 4-week run-in period during which LABA treatment was stopped. Subjects reporting symptoms and/or rescue beta<sub>2</sub>-agonist medication use during the run-in period were continued in the trial. Mean baseline percent predicted FEV<sub>1</sub> was approximately 70% across treatment groups.

At Week 12, change from baseline in weighted mean FEV<sub>1</sub> (0 to 24 hours) in a subset of patients (n=309) was significantly greater for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared with placebo and numerically greater than fluticasone furoate 100 mcg, but not statistically significant ([Table 11](#)).


At Week 12, change from baseline in trough FEV<sub>1</sub> was significantly greater for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared with placebo and numerically greater than fluticasone furoate 100 mcg, but not statistically significant ([Table 11](#)).

**Table 11**      **Change from Baseline in Weighted Mean FEV<sub>1</sub> (0-24 h) (mL) and Trough FEV<sub>1</sub> (mL) at Week 12 (HZA106827)**

	<b>BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (n=108)</b>
<b>Weighted Mean FEV<sub>1</sub></b>	
Difference vs. fluticasone furoate 100 mcg (n=106)	116
95% CI	-5, 236
<i>P</i> value	0.060
Difference vs. placebo (n=95)	302
95% CI	178, 426
<i>P</i> value	<0.001
<b>Trough FEV<sub>1</sub></b>	<b>(n=200)</b>
Difference vs. fluticasone furoate 100 mcg (n=203)	36
95% CI	-48, 120
<i>P</i> value	0.405
Difference vs. placebo (n=193)	172
95% CI	87, 258
<i>P</i> value	<0.001

Lung function improvements were sustained over the 24-hour period following the final dose of BREO<sup>®</sup> ELLIPTA<sup>®</sup> as demonstrated by serial FEV<sub>1</sub> measurements taken at 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours (Figure 5).

**Figure 5 Mean Change From Baseline in Individual Serial FEV<sub>1</sub> (mL) Assessments Over 24 Hours After 12 Weeks of Treatment (HZA106827)**



**HZA116863**

HZA116863 was a 12-week trial that evaluated the efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg, BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg, and fluticasone furoate 100 mcg in subjects with asthma. Subjects receiving mid- to high-dose inhaled corticosteroid (greater than or equal to fluticasone propionate 250 mcg twice daily or equivalent) or a mid-dose inhaled corticosteroid plus a LABA (fluticasone propionate/salmeterol 250 mcg/50 mcg twice daily or equivalent) entered a 4-week run-in period during which LABA treatment was stopped. Subjects reporting symptoms and/or rescue beta<sub>2</sub>-agonist medication use during the run-in period were continued in the trial. Mean baseline percent predicted FEV<sub>1</sub> was 61.13% to 62.64% across treatment groups.

At Week 12, the change from baseline in weighted mean FEV<sub>1</sub> (0 to 24 hours) was significantly greater for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared with fluticasone furoate 100 mcg (Table 12). In a descriptive analysis, the change from baseline in weighted mean FEV<sub>1</sub> (0 to 24 hours) for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg was numerically greater than BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (24 mL, 95% CI: -37, 86).

**Table 12 Change From Baseline in Weighted Mean FEV<sub>1</sub> (0-24 h) (mL) at Week 12 in HZA116863**

	<b>BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg</b>
<b>Weighted Mean FEV<sub>1</sub></b>	<b>(n=312)</b>
Difference vs. fluticasone furoate 100 mcg (n=288)	108
95% CI	45, 171
<i>P</i> value	<0.001

At Week 12, the change from baseline in the powered secondary endpoint, trough FEV<sub>1</sub> was significantly greater for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (n=334) compared with fluticasone furoate 100 mcg (n=336) (77 mL, 95% CI: 16, 138; *P* = 0.014). In a descriptive analysis, the change from baseline in trough FEV<sub>1</sub> for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg (n=337) was numerically greater than BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (16 mL, 95% CI: -46, 77).


Subjects receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg had a significantly greater improvement from baseline over the 12-week treatment period in percentage of 24-hour periods without need of beta<sub>2</sub>-agonist rescue medication use, another powered secondary endpoint, compared with subjects receiving fluticasone furoate 100 mcg (12.2%, which equates to an additional 0.9 days per week without need for rescue medication).

Subjects receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg had a significantly greater improvement from baseline in percentage of 24-hour periods without asthma symptoms compared with subjects receiving fluticasone furoate 100 mcg (7.8%, which equates to an additional 0.5 days per week without asthma symptoms). Although not specified as a powered secondary endpoint, the percentage of 24-hour periods without asthma symptoms was included in the pre-defined statistical plan.

Lung function improvements were sustained over the 24-hour period following the final dose of BREO<sup>®</sup> ELLIPTA<sup>®</sup> as demonstrated by serial FEV<sub>1</sub> measurements taken at 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours (Figure 6).



**Figure 6 Mean Change From Baseline in Individual Serial FEV<sub>1</sub> (mL) Assessments Over 24 Hours After 12 Weeks of Treatment (HZA116863)**



**HZA106829**

HZA106829 was a 24-week trial that evaluated the efficacy of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg once daily, fluticasone furoate 200 mcg once daily, and fluticasone propionate 500 mcg twice daily in subjects with asthma. Subjects receiving high-dose inhaled corticosteroid (fluticasone propionate 500 mcg twice daily or equivalent) or a mid-dose inhaled corticosteroid plus a LABA (fluticasone propionate/salmeterol 250 mcg/50 mcg twice daily or equivalent) entered a 4-week run-in period during which LABA treatment was stopped. Subjects reporting symptoms and/or rescue beta<sub>2</sub>-agonist medication use during the run-in period were continued in the trial. Mean baseline percent predicted FEV<sub>1</sub> was approximately 67% across treatment groups.

The change from baseline in weighted mean FEV<sub>1</sub> (0 to 24 hours) and in trough FEV<sub>1</sub> was significantly greater for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg compared with fluticasone furoate 200 mcg (Table 13).

**Table 13 Change From Baseline in Weighted Mean FEV<sub>1</sub> (0-24 h) (mL) and Trough FEV<sub>1</sub> (mL) Week 24 (HZA106829)**


	<b>BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg</b>
<b>Weighted Mean FEV<sub>1</sub></b>	<b>(n=89)</b>
Difference vs. fluticasone furoate 200 mcg (n=83)	136
95% CI	1, 270
<i>P</i> value	0.048
<b>Trough FEV<sub>1</sub></b>	<b>(n=187)</b>
Difference vs. fluticasone furoate 200 mcg (n=186)	193
95% CI	108, 277
<i>P</i> value	<0.001

The change from baseline in weighted mean FEV<sub>1</sub> (0 to 24 hours) was significantly greater for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg compared with fluticasone propionate 500 mcg twice daily (206 mL, 95% CI: 73, 339; *P* = 0.003) at Week 24. The change from baseline in trough FEV<sub>1</sub> was significantly greater for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg compared with fluticasone propionate 500 mcg twice daily (210 mL, 95% CI: 127, 294; *P*<0.001) at Week 24.

Subjects receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg had a significantly greater improvement from baseline in percentage of 24-hour periods without need of beta<sub>2</sub>-agonist rescue medication use, a powered secondary endpoint, compared with subjects receiving fluticasone furoate 200 mcg (11.7%, which equates to an additional 0.8 days per week without need for rescue medication). Subjects receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup> 200/25 mcg had a significantly greater improvement from baseline in percentage of 24-hour periods without asthma symptoms compared with subjects receiving fluticasone furoate 200 mcg (8.4%, which equates to an additional 0.6 days per week without asthma symptoms). Although not specified as a powered secondary endpoint, the percentage of 24-hour periods without asthma symptoms was included in the pre-defined statistical plan.

Lung function improvements were sustained over the 24-hour period following the final dose of BREO<sup>®</sup> ELLIPTA<sup>®</sup> as demonstrated by serial FEV<sub>1</sub> measurements taken at 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours (Figure 7).

**Figure 7 Mean Change From Baseline in Individual Serial FEV<sub>1</sub> (mL) Assessments Over 24 Hours After 24 Weeks of Treatment (HZA106829)**



**Exacerbation study**

Trial HZA106837 was a 24- to 76-week event-driven exacerbation trial that evaluated whether BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg significantly decreased the risk of asthma exacerbations as measured by time to first asthma exacerbation when compared with fluticasone furoate 100 mcg in subjects with asthma. Subjects receiving low- to high-dose inhaled corticosteroid (fluticasone propionate 100 mcg to 500 mcg twice daily or equivalent) or low- to mid-dose inhaled corticosteroid plus a LABA (fluticasone propionate/salmeterol 100 mcg/50 mcg to 250 mcg/50 mcg twice daily or equivalent) and a history of 1 or more asthma exacerbations that required treatment with oral/systemic corticosteroid or emergency department visit or in-patient hospitalization for the treatment of asthma in the year prior to trial entry, entered a 2-week run-in period during which LABA treatment was stopped. Subjects reporting symptoms and/or rescue beta<sub>2</sub>-agonist medication use during the run-in period were continued in the trial. Mean baseline percent predicted FEV<sub>1</sub> was approximately 72% across treatment groups.

This trial was of variable treatment duration (from a minimum of 24 weeks to a maximum of 76 weeks with the majority of patients treated for at least 52 weeks). Patients were randomized to receive either BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg or fluticasone furoate 100 mcg both administered once daily. The primary endpoint was the time to first severe asthma exacerbation. A severe asthma exacerbation was defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.

In HZA106837, the risk of experiencing a severe asthma exacerbation in patients receiving BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg was 12.8% compared to 15.9% for fluticasone furoate 100 mcg. This represents a relative reduction of 20% (hazard ratio 0.795; 95% CI 0.642, 0.985;  $P=0.036$ ). The rate of severe asthma exacerbations per patient per year was 0.19 for fluticasone furoate 100 mcg (approximately 1 in every 5 years) and 0.14 for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg (approximately 1 in every 7 years). The ratio of the exacerbation rate for BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg versus fluticasone furoate 100 mcg was 0.755 (95% CI 0.603, 0.945). This represents a 25% reduction in the rate of severe asthma exacerbations.

The 24-hour bronchodilator effect of fluticasone furoate/vilanterol was maintained throughout a one-year treatment period with no evidence of loss in efficacy (no tachyphylaxis).

## **DETAILED PHARMACOLOGY**

### **Animal Pharmacology**

Pharmacological and toxicological effects seen with fluticasone furoate or vilanterol in nonclinical studies were those typically associated with either glucocorticoids or beta<sub>2</sub>-agonists. Administration of fluticasone furoate combined with vilanterol did not result in any significant new toxicity.

### **Clinical Pharmacology**

#### ***HPA Axis Effects***

Inhaled fluticasone furoate at repeat doses up to 400 mcg was not consistently associated with statistically significant decreases in serum or urinary cortisol in healthy subjects. At higher doses above the therapeutic range decreases in serum and urine cortisol levels were seen.

Population pharmacokinetic/pharmacodynamic meta-analyses were conducted to characterize the relationship between fluticasone furoate AUC(0-24) and 24-hour weighted mean serum cortisol and between fluticasone furoate AUC(0-24) and 24-hour urinary cortisol excretion. The population studied comprised healthy subjects and patients with asthma. The average estimate of fluticasone furoate AUC(0-24) required to reduce cortisol by 50% (AUC50) was similar for both the serum and urine cortisol models with

values of 1,556 and 1,686 pg•hr/mL, respectively. These values of AUC50 are several-fold higher than average fluticasone furoate AUC(0-24) values observed at the therapeutic dose of 100 mcg in subjects with COPD (182 pg•hr/mL) and the highest dose of 200 mcg for subjects with asthma (495 pg•hr/mL).

In a subset of subjects with COPD in two 6-month lung function trials, treatment with fluticasone furoate/ vilanterol (50/25 mcg, 100/25 mcg, 200/25 mcg), and fluticasone furoate (100 and 200 mcg), showed no effect on 24-hour urinary cortisol excretion.


In a trial with subjects with asthma, treatment with fluticasone furoate/vilanterol (100/25 mcg and 200/25 mcg) for 6 weeks did not affect 24-hour serum cortisol.

In subjects with COPD treated with fluticasone furoate/ vilanterol (50/25 mcg, 100/25 mcg and 200/25 mcg) for 28 days, no effects on serum cortisol were observed.

***Duration and Persistence of Effects on Lung Function***

The 24-hour spirometric effect of BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared with placebo was evaluated at the end of a 28-day study treatment period in 54 patients with COPD in a randomized, double-blind, 3-way, incomplete block crossover study. BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg demonstrated statistically significant increases in weighted mean FEV<sub>1</sub> compared with placebo on the final day of treatment. As shown in [Figure 8](#) improvements in lung function over a full 24 hours were sustained.

**Figure 8 Change From Baseline in FEV<sub>1</sub> (0-25 hours) Over Days 28 and 29**



**Notes:**  
FF/VI: BREO<sup>®</sup> ELLIPTA<sup>®</sup>

The difference in weighted mean FEV<sub>1</sub> (0-24 hr) over days 28 and 29 following BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg compared with placebo was 220 mL (95% CI 165, 275, *P*<0.001). In addition, trough FEV<sub>1</sub> on Day 29 was significantly higher for BREO<sup>®</sup> ELLIPTA<sup>®</sup>. The difference in trough FEV<sub>1</sub> with BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100/25 mcg with placebo was 177 mL (95% CI 97, 257, *P*<0.001).

## TOXICOLOGY

### Fluticasone furoate

Fluticasone furoate (FF) has undergone a comprehensive toxicological evaluation, and the principal findings are summarised in [Table 14](#). In the majority of studies, fluticasone furoate was administered by the inhaled route which resulted in systemic exposure. The major findings were typically associated with systemic exposure to glucocorticoids, and are commonly reported for other marketed inhaled corticosteroids. In patients following repeated inhaled doses of 100 or 200 mcg/day plasma concentrations of fluticasone furoate were typically lower than those achieved in animal toxicology studies (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).

**Table 14 Summary of Principal Findings in Fluticasone Furoate Toxicology Studies**

Study Type & Duration	Route	Species	Dose mcg/kg/day, unless indicated)	Noteworthy Findings
Single Dose	oral intravenous inhalation	mouse	1000, 1500, 2000 (mg/kg) 18000, 30000 7100	Findings following high single doses included reduced body weight and lymphoid depletion. Gastric irritation was seen following high dose oral administration in rats.
	oral intravenous inhalation	rat	1000, 1500, 2000 (mg/kg) 12000, 18000 4400	
<sup>a</sup> Repeat Dose 4 weeks	inhalation	rat	6.9, 17.6, 71.7 6.5, 19.5, 72.0	Findings following repeated inhalation administration of FF included suppressed weight gain,

Study Type & Duration	Route	Species	Dose mcg/kg/day, unless indicated)	Noteworthy Findings
		dog	10.6, 30.6, 105 9, 22, 74	
13 weeks	inhalation	mouse	7.3, 18.6, 76.9	
		rat	4.3, 8.5, 24.3	
		dog	11.3, 33.0, 64.7	
26 weeks	inhalation	rat	3.2, 8.3, 20.3	
39 weeks	inhalation	dog	13.3, 30.1, 59.6	
<b>Repeat Dose</b> 14 days	intranasal	rat (male)	80, 160 (mcg/day)	In intranasal studies, findings following administration of FF were similar to those seen following inhalation administration. In the 26 week dog study, local effects were confined to increased numbers of goblet cells in the nasal epithelium, considered an adaptive response to local administration of suprathreshold levels of FF.
4 weeks	intranasal	dog	400, 1200 (mcg/day)	
13/26 weeks	intranasal	dog	1200, 2400 (mcg/day)	
<b>Genotoxicity</b> AMES Mouse lymphoma	<i>In vitro</i>	NA*	up to 1000 (mcg/plate) up to 25 (mcg/mL)	FF did not cause gene mutation in bacteria or chromosomal damage in mammalian cells <i>in vitro</i> .
Micronucleus (2 doses, 24 hours apart)	intravenous	rat	625, 1000 1000, 2000, 4000 10000, 20000, 40000	There was no evidence of genotoxicity in the <i>in vivo</i> micronucleus tests in rats.
<b>Carcinogenicity</b> 104 weeks	Inhalation	mouse	2.2, 6.1, 18.8	There was no evidence of treatment-related increases in tumour incidence in two year inhalation studies in rats and mice.
		rat	1.0, 3.2, 8.6	
<sup>b</sup> <b>Reproductive Toxicity</b> Male fertility 69 to 73 days (from 28 days prior to co- habitation)	inhalation	rat	6.6, 12.9, 29.4	There were no effects on mating performance or fertility of male or female rats. Developmental toxicity in rats was confined to an increased incidence of incompletely ossified sternabrae in association with lower fetal weight. High doses in rabbits (46.6 mcg/kg/day) induced abortion. There were no major skeletal or visceral abnormalities in either rats or rabbits, and no effect on pre- or post-natal development in rats treated with FF during gestation and lactation.

<b>Study Type &amp; Duration</b>	<b>Route</b>	<b>Species</b>	<b>Dose mcg/kg/day, unless indicated)</b>	<b>Noteworthy Findings</b>
FFEEEFD** 41 to 46 days (from 14 days prior to mating until Day 17 of pregnancy)	inhalation	rat	11, 23, 91	The developmental NOAEL in female rats achieved systemic exposures approximately 3-fold greater than in patients with asthma receiving FF 200 mcg/day <sup>a</sup> ; this dose is similar to the NOAEL in the male fertility and PPN studies in which TK data were not collected; AUC data for the NOAEL could not be calculated for the rabbit EFD study, but, at NOAEL, C <sub>max</sub> was approximately 4-fold greater than in patients with asthma receiving FF, 200mcg/day <sup>a</sup> .
EFD*** 13 days (from Days 8 to 20 of pregnancy)	inhalation	rabbit	9.7, 46.6, 85.1 1.8, 3.2, 8.1	
PPN**** 35 days (from Days 6 to 20pc and Days 2 to 21pp)	inhalation	rat	5.5, 15.7, 27.2	
Juvenile***** 14 Days	inhalation,	rat,	7.9, 27, 73	In juvenile rats and dogs findings were consistent with the corticosteroid effects of FF seen in adult animals.
		dog	9.8, 23.4, 47.6	
28 days	intranasal	dog	800 (µg/day)	
<b>Local Tolerance</b> Dermal irritancy 4 hours 16 hours	topical	rabbit	500 (mcg) 0.2 (mcg/mL)	FF was non-irritating following single dose application to the skin, and practically non-irritating following application of the intranasal clinical formulation to the eye.
Ocular irritancy Single dose	topical	rabbit	0.05% (w/w)	
<b>Other Toxicity</b> Respiratory hypersensitivity 5 days	inhalation	guinea pig (male)	67.1 to 71.2	There was no evidence of respiratory hypersensitivity reactions following inhalation administration of FF.
<p>Key:  *NA = Not applicable  **FFEEEFD = Female fertility, early embryonic and embryofetal development  *** EFD = Embryofetal development  **** PPN =Pre- and post-natal development  *****At start of dosing juvenile rats were aged approximately 21 days and juvenile dogs were aged approximately 8 weeks  pc = post-coitum  pp = post partum  a = Model predicted geometric mean systemic exposure following administration of 200 mcg FF (in combination with VI) in subjects with asthma = 0.0314 ng/mL (C<sub>max</sub>) or 0.495 ng.h/mL (AUC)</p>				



## Vilanterol

Vilanterol (VI) has undergone a comprehensive toxicological evaluation, and the principal findings are summarised in [Table 15](#). In the majority of studies, VI was administered by the inhaled route which resulted in systemic exposure. The major findings were typically associated with systemic exposure to beta<sub>2</sub> agonists and are commonly reported for other marketed LABAs. In patients following repeated inhaled doses of 25 mcg/day plasma concentrations of vilanterol were typically lower than those achieved in animal toxicology studies (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).

**Table 15 Summary of Principal Findings in Vilanterol Toxicology Studies**

Study Type & Duration	Route	Species	Dose (mcg/kg/day, unless indicated)	Noteworthy Findings
Single Dose	oral	rat	5, 30, 100, 300 (mg/kg)	Single dose toxicity studies were not conducted with VI, however in single dose tolerability studies, high oral doses in rats were well-tolerated and in dogs single inhaled doses were associated with vasodilatation increased pulse rate and serum cardiac troponin I.
	inhalation	dog	H <sub>135</sub>	
<sup>a</sup> Repeat Dose 2 weeks	oral	mouse	1000, 10000, 50000	Findings following repeated inhalation administration of high doses of VI to mice, rats or dogs included severe clinical signs (underactive behaviour, irregular and/or laboured breathing and half closed eyelids), tachycardia, increased weight gain, variable changes in a number of clinical chemistry(e.g. increased alkaline phosphatase concentrations) and haematology endpoints, upper respiratory tract irritancy, skeletal muscle myofibre degeneration, myocardial fibrosis/necrosis and transient increases in serum cardiac troponin I, thymic involution, increased periportal hepatocyte rarefaction/decreased centrilobular hepatocyte rarefaction, myometrial hyperplasia, increased acinar development and secretory activity in mammary gland, decreased corpora lutea and abnormal oestrus cycles and increased incidence/severity of ovarian cysts.
	inhalation	mouse	H <sub>51</sub> , 1164, 5814, 48972	
		rat	H <sub>50.4</sub> , 250.8, 771.6	
		dog	10,33,137	
4 weeks	inhalation	rat	H <sub>45.1</sub> , 261.1, 708.7	
13 weeks	inhalation	mouse	58.6, 1020, 6490, 38200	
		rat	56.2, 657.9, 10392.6, 38845.1	
		dog	9.31, 66.0, 501	
26 weeks	inhalation	rat	57.7 <sup>F</sup> , 537, 2674, 10253 <sup>M</sup>	

Study Type & Duration	Route	Species	Dose (mcg/kg/day, unless indicated)	Noteworthy Findings
39 weeks	inhalation	dog	9.55, 62.5, 510	At the NOAEL in repeat dose toxicity studies of up to 39 weeks duration, compared with systemic exposures seen in asthma subjects receiving 25 mcg/day VI <sup>b</sup> , AUC exposures were ≥ 30X or >4000X greater in female or male rats, respectively, ≥ 34X in dogs and 3480X in mice.
<b>Genotoxicity</b> Ames Mouse lymphoma SHE**	<i>In vitro</i>	NA*	up to <sup>H</sup> 5000 mcg/plate up to <sup>H</sup> 35 mcg/mL up to <sup>H</sup> 32.5 mcg/mL	VI was not mutagenic in bacteria, did not induce morphological transformation in a Syrian hamster embryo assay, but did induce an equivocal, non-reproducible response at highly cytotoxic concentrations in the presence of S9-mix in a mouse lymphoma assay. VI was not genotoxic in vivo in the rat micronucleus or unscheduled DNA synthesis (UDS) assays.
Micronucleus (2 doses, 24 hours apart)	intravenous	rat	<sup>H</sup> 7800, 12500	
UDS*** (2 doses, 14 hours apart)			<sup>H</sup> 3750, 12500	
<b>Carcinogenicity</b> 104 weeks	inhalation	mouse	6.4, 62, 615, 6150, 29500	In two-year inhalation carcinogenicity studies, proliferative changes were seen in the female reproductive tract (mesovarian/periovarian smooth muscle hypertrophy / hyperplasia, mesovarian leiomyoma in rats; ovarian tubulostromal adenomas and hyperplasia, ovarian sex-cord stromal tumours and hyperplasia, uterine smooth muscle hypertrophy/hyperplasia, leiomyomas, leiomyosarcomas and cystic endometrial hyperplasia in mice) and pituitary gland (shortening of latency for pituitary neoplasms). There was also an increased incidence of ovarian cysts in both species.  There was no statistically significant, treatment-related increase in tumor incidence at 615 or 10.5 mcg/kg/day in mice or rats, respectively.
		rat	10.5/3.47 <sup>a</sup> , 84.4/28.2 <sup>a</sup> , 84.4 <sup>a</sup> , 223, 657	
<sup>b</sup> <b>Reproductive Toxicity</b> Male fertility 54 to 57 days (from 14 days prior to mating)	inhalation	rat	62, 824, 31508	Inhaled administration of VI to rats did not affect fertility in either males or females and did not cause any adverse effects on litter parameters or the developing fetus and there were no adverse effects on pre- or post-natal development after oral administration to female rats. In rabbits, administration of VI by inhaled or subcutaneous routes resulted in fetal abnormalities (low
FFEED**** 22 to 33 days (from 2 weeks prior to mating)	inhalation	rat	49.4, 664, 37112	

Study Type & Duration	Route	Species	Dose (mcg/kg/day, unless indicated)	Noteworthy Findings
to Day 6 pc)				incidence of cleft palate, open eyelids, sternebral fusion and/or an abnormal pattern of frontal bone ossification).  Using TK data from repeat-dose toxicity studies, the developmental NOAEL, exposures were approximately 8000X those achieved in subjects with asthma given 25 mcg/day VI <sup>b</sup> and in rabbits, the NOAEL following subcutaneous administration was 133X, but a NOAEL was not identified in rabbits following inhaled administration.
EFD***** 12 days (from Days 6 to 17 pc)	inhalation	rat	45.4, 613, 33733	
13 days (from Days 7 to 19 pc)	Inhalation subcutaneous	rabbit	62.7, 591, 5740 3,7,30,300	
PPN***** 35 days (from Day 6 pc to Day 20 pp)	oral	rat	300, 3000, 10000	
<b>Local Tolerance</b> Local lymph node 3 days	topical	mouse	50 mcL of 50% (w/w)	VI was non-sensitising in mouse local lymph node assay and was shown to be non-irritant to skin and not a severe irritant to the eye in reconstructed/reconstituted human tissue.
Dermal irritancy	topical	NA*	25 mg	
Ocular irritancy	topical	NA*	30 mg	
<p>Key:  NA = Not applicable  ** SHE = Syrian hamster embryo  *** UDS = Unscheduled DNA synthesis  **** FFEED = Female fertility and early embryonic development  ***** EFD = Embryofoetal development  ***** PPN =Pre- and post-natal development  pc = post-coitum  pp = post partum  a = In week 86, the dose was reduced for female rats from 84.4 to 28.2 mcg/kg/day and from 10.5 to 3.47 mcg/kg/day  b = Model predicted geometric mean systemic exposure following administration of 25 mcg VI (alone or in combination with FF) in subjects with asthma = 0.0495 ng/mL (Cmax) or 0.169 ng.h/mL (AUC)  H = study conducted with <math>\alpha</math>-phenylcinnamate (H) salt of VI</p>				

## Fluticasone Furoate combined with Vilanterol

Fluticasone Furoate (FF) combined with Vilanterol (VI) has been evaluated in a number of studies, and the principal findings are summarised in [Table 16](#). Findings were consistent with those seen in studies with FF or VI alone and the effects of FF tended to predominate. The major findings were those typically associated with systemic exposure to glucocorticoids or beta<sub>2</sub> agonists, and which are commonly reported for other marketed products with the same pharmacological targets. No studies of carcinogenicity, genotoxicity, single dose toxicity, local tolerance or impairment of fertility were conducted using fluticasone furoate and vilanterol in combination.

**Table 16 Summary of Principal Findings in Fluticasone Furoate and Vilanterol Combination Toxicology Studies**

<b>Study Type &amp; Duration</b>	<b>Route</b>	<b>Species</b>	<b>Dose (mcg/kg/day; FF/VI)</b>	<b>Noteworthy Findings</b>
<b>Repeat Dose</b> 4 weeks	inhalation	rat	34.9/0; 0/6.29; 33.5/8.31; 29.4/18.7; 33.0/25.5	With the exception of increased mammary gland secretion in rats and altered glycogen distribution in dogs, the effects in the combination groups were generally similar in nature and/or incidence to changes observed in rats or dogs exposed to FF or VI alone. Treatment related effects increased with the fluticasone furoate dose.
4 weeks	inhalation	dog	33.8/0; 0/0.953; 35.2/1.27; 33.3/3.71; 34.9/4.18	
13 weeks	inhalation	rat	56.4/0; 0/24.9; 7.85/5.24; 19.8/11.7; 53.8/30.7; 52.6/5.82	
13 weeks	inhalation	dog	56.1/0; 0/33.5; 6.92/3.81; 20.6/11.7; 63.9/35.0; 61.0/1.17	
<b><sup>a</sup>Reproductive Toxicity</b> EFD** 12 days (from Days 6 to 17 pc)	inhalation	rat	82.0/0; 94.4/3.5; 94.9/98.3; 0/86.9; 7.9/8.3; 29.5/31.7	In FF/VI combination groups, findings were similar to those seen with FF alone in particular fetal growth retardation through an increase in litters with unossified or incomplete ossification of the sternebra and xiphisternum.
Juvenile*** (14 days)	inhalation	rat	41.8/0; 0/20.4; 0/629.8; 32.8/18.8; 26.2/3.6	In juvenile toxicity studies, findings were generally typical of a corticosteroid or a beta2-agonist and no novel toxicity was seen with the combination. Although the majority of changes were also seen in inhalation toxicity studies in adult animals, some findings in kidney, eyes, bone, lungs and teeth associated with FF treatment, were only seen in juvenile dogs.
		dog	43.1/26.8; 39.8/1.1; 27.1/0; 0/30.6; 0/94.1	
Juvenile*** 13 weeks	inhalation	dog	59.9/0; 0/51.6; 7.07/9.32; 18.6/19.1; 57.8/62.0; 57.5/5.38	
<p>Key:  ** <b>EFD</b> = Embryofoetal development  <b>pc</b> = post-coitum</p>				

## REFERENCES

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C. Effect of Once-Daily Fluticasone Furoate/Vilanterol on 24-Hour Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease: A Randomized, Three-Way, Incomplete Block, Crossover Study. *Clin Ther.* 2012; Jul 34 (8):1655-66.

Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, Lettis S, Barnhart F, Haumann B. The efficacy and safety of the novel long-acting  $\beta_2$  agonist vilanterol in patients with COPD: A randomized placebo-controlled trial. *Chest.* 2012 Jul 142 (1):119-27.

## PART III: CONSUMER INFORMATION

**Pr**BREO<sup>®</sup> ELLIPTA<sup>®</sup>  
**fluticasone furoate/vilanterol**  
**dry powder for oral inhalation**

This leaflet is part III of a three-part "Product Monograph" published when BREO<sup>®</sup> ELLIPTA<sup>®</sup> was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about BREO<sup>®</sup> ELLIPTA<sup>®</sup>. Contact your doctor or pharmacist if you have any questions about the drug.

### ABOUT THIS MEDICATION

#### What the medication is used for:

**Chronic Obstructive Pulmonary Disease (COPD):**  
 BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100 mcg/25 mcg is the only strength indicated for the treatment of COPD.

BREO<sup>®</sup> ELLIPTA<sup>®</sup> (100 mcg/25 mcg) is used:

- For the long-term treatment of chronic obstructive pulmonary disease (COPD).
- To reduce the likelihood of "flare-ups" in people with COPD who have previously had these events.

You will know you are having a "flare-up" if two of the following symptoms get worse for more than two days in a row:

- Unusual increase in the severity of breathlessness; cough, wheezing, or fatigue;
- Unusual colour, amount or thickness of mucus;
- Tightness in the chest or symptoms of a cold

#### **Asthma:**

BREO<sup>®</sup> ELLIPTA<sup>®</sup> 100 mcg/25 mcg and 200 mcg/25 mcg are the strengths indicated for the treatment of asthma.

BREO<sup>®</sup> ELLIPTA<sup>®</sup> (100 mcg/25 mcg and 200 mcg/25 mcg) is used for the long term treatment of asthma in people aged 18 years and older.

#### What it does:

BREO<sup>®</sup> ELLIPTA<sup>®</sup> contains two active ingredients, fluticasone furoate and vilanterol.

- Fluticasone furoate is an inhaled corticosteroid (ICS). It reduces inflammation in the airways of the lungs, which can ease breathing problems in COPD and asthma, and helps prevent "flare-ups" in COPD.
- Vilanterol is a long-acting beta<sub>2</sub> agonist (LABA). It helps to open and relax the muscles in the airways. This allows more air to get in and out of the lungs and helps prevent shortness of breath and wheezing.

This medicine does not cure COPD or asthma but helps to control it.

#### When it should not be used:

Do not use BREO<sup>®</sup> ELLIPTA<sup>®</sup>:

- To treat sudden severe symptoms of COPD or asthma such as sudden shortness of breath or wheezing. **BREO<sup>®</sup> ELLIPTA<sup>®</sup> is not a rescue inhaler and should not be used to give you fast relief from your COPD or asthma attack.** You must use a rescue inhaler during a sudden COPD or asthma attack.
- If you are under 18 years of age;
- If you are allergic to any of the medicinal or nonmedicinal ingredients contained in the product;
- If you have a lactose or severe milk protein allergy.

#### What the medicinal ingredients are:

Fluticasone furoate and vilanterol.

#### What the nonmedicinal ingredients are:

Lactose monohydrate (which contains milk proteins) and magnesium stearate.

#### What dosage forms it comes in:

Dry Powder for Oral Inhalation: 100 mcg/25 mcg and 200 mcg/25 mcg.

The dry powder is contained in a series of separate blisters and is delivered by the ELLIPTA<sup>®</sup> inhaler. Each dose contains 100 or 200 mcg of fluticasone furoate and 25 mcg of vilanterol.

Each inhaler contains 30 doses (one inhalation per day for 30 days).

If a sample is given to you by your doctor, it will contain 14 doses (one inhalation per day for 14 days).

**WARNINGS AND PRECAUTIONS****Warning – Asthma Related Death**

You are advised that in patients with asthma, long-acting beta<sub>2</sub>-agonist (LABA) medicines increase the chance of death from asthma problems. In a large asthma study, more patients who used another LABA medicine (salmeterol) died from asthma problems compared with patients who did not use that LABA medicine. This finding may also apply to BREO<sup>®</sup> ELLIPTA<sup>®</sup>.

- **Your doctor will assess your asthma control at regular intervals. BREO<sup>®</sup> ELLIPTA<sup>®</sup> should only be used when your doctor decides that other asthma medications (e.g. inhaled corticosteroids along with a rescue inhaler) are not helping you enough, or that you need two maintenance medications to control your asthma.**
- **BREO<sup>®</sup> ELLIPTA<sup>®</sup> should not be the first medication you use, unless advised by your doctor.**

**Once asthma control has been achieved and maintained, your doctor will assess you at regular intervals. BREO<sup>®</sup> ELLIPTA<sup>®</sup> should only be used when an inhaled corticosteroid does not adequately control your asthma symptoms.**

**BEFORE you use BREO<sup>®</sup> ELLIPTA<sup>®</sup>, talk to your doctor or pharmacist if you:**

- Have liver disease, as you may be more likely to experience side effects;
- Have heart problems, irregular heart beat or high blood pressure;
- Are pregnant or planning to become pregnant;
- Are breastfeeding;
- Have ever had thrush or a yeast infection in your mouth;
- Have ever had seizures;
- Have thyroid gland problems or disease;
- Have diabetes;
- Have ever had to stop taking another medication for your breathing problems because you were allergic to it or it caused problems;
- Have been taking other corticosteroids by mouth or by inhalation;
- Have an immune system problem;
- Have any allergies to food or drugs;
- Have low levels of potassium in your blood;
- Have ever had herpes simplex of the eye, a history of tuberculosis infections, or any type of viral, bacterial, fungal (yeast), or parasitic infection.

**BREO<sup>®</sup> ELLIPTA<sup>®</sup> is not for the treatment of acute asthma attacks or sudden increase of breathlessness and wheezing in COPD.** If you get a sudden attack of wheezing and breathlessness between your doses of BREO<sup>®</sup> ELLIPTA<sup>®</sup>, you should use your fast acting 'reliever' medicine, such as salbutamol (e.g. VENTOLIN<sup>®</sup>) which your doctor has prescribed to you. Use the medication as directed by your doctor.

If you no longer take an oral corticosteroid you should carry a warning card indicating that you may need supplementary corticosteroid treatment during periods of stress or a COPD flare-up.

Do not use other medicines that contain a LABA for any reason. Ask your healthcare provider or pharmacist if any of your other medicines are LABA medicines.

When using drugs like BREO<sup>®</sup> ELLIPTA<sup>®</sup> for long term treatment, you may be at risk of:

- Breaking a bone (bone fractures);
- Weak bones (osteoporosis; increased risk of bone fractures).

Take extra care to avoid any injury, especially falls.

You should avoid coming into contact with people who have measles or chicken pox while taking BREO<sup>®</sup> ELLIPTA<sup>®</sup>. If you are exposed, tell your doctor right away.

Drugs like BREO<sup>®</sup> ELLIPTA<sup>®</sup> can cause Eye Disorders:

- Cataracts: clouding of the lens in the eye, blurry vision, eye pain;
- Glaucoma: an increased pressure in your eyes, eye pain. Untreated, it may lead to permanent vision loss;
- You should therefore have regular eye exams.

**Pregnancy:**

**BREO<sup>®</sup> ELLIPTA<sup>®</sup> is not usually recommended for use during pregnancy.**

Before prescribing BREO<sup>®</sup> ELLIPTA<sup>®</sup> your doctor will consider the benefit to you and the risk to your unborn baby.

**Breastfeeding/ Lactation:**

It is not known whether the ingredients of BREO<sup>®</sup> ELLIPTA<sup>®</sup> can pass into breast milk. If you are breastfeeding, **check with your doctor** before you take BREO<sup>®</sup> ELLIPTA<sup>®</sup>.

**COPD:** Tell your doctor immediately if you notice symptoms of a "flare up".

Patients with COPD have a higher chance of getting pneumonia (a lung infection). Drugs like BREO<sup>®</sup> ELLIPTA<sup>®</sup> may also increase your chance of getting pneumonia. However, symptoms of pneumonia and COPD ‘flare ups’ frequently overlap. It is therefore important that you tell your doctor immediately if you suspect an infection as even mild chest infections should be treated immediately. Your doctor may also recommend that you receive a flu shot each year.

**Asthma:** Tell your doctor immediately if:

- There is a change in your symptoms such as more coughing, attacks of wheezing, chest tightness, or an unusual increase in the severity of the breathlessness.
- You wake up at night with chest tightness, wheezing or shortness of breath.
- You are using increasing amounts of your fast acting ‘reliever’ medicine.

These could be warning signs that your condition may be worsening. Do not stop taking BREO<sup>®</sup> ELLIPTA<sup>®</sup> without talking to your doctor.

### INTERACTIONS WITH THIS MEDICATION

As with most medicines, interactions with other drugs are possible. Tell your doctor, nurse, or pharmacist about all the medicines you take, including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines.

Drugs that may interact with BREO<sup>®</sup> ELLIPTA<sup>®</sup> include:

- Ketoconazole used to treat fungal infections;
- Anti-HIV medicines;
- Clarithromycin used to treat bacterial infections;
- Beta-blockers used to lower blood pressure (e.g. propranolol) or for other heart or eye problems (e.g. timolol);
- Medicines to decrease the level of potassium in your blood (i.e. diuretics). These are also known as “water pills” and are used to lower blood pressure;
- Medicines used in the treatment of depression (i.e. antidepressants, monoamine oxidase inhibitors).

### PROPER USE OF THIS MEDICATION

BREO<sup>®</sup> ELLIPTA<sup>®</sup> does not relieve sudden symptoms. Always have a rescue inhaler with you to treat sudden symptoms. If you do not have a rescue inhaler, call your healthcare provider to have one prescribed for you.

You should also try to avoid potential asthma triggers such as dust mites, mold, pets, tobacco smoke and pollen.

It is important that you continue to take BREO<sup>®</sup> ELLIPTA<sup>®</sup> regularly even if you feel fine and do not have any symptoms.

Do not stop taking BREO<sup>®</sup> ELLIPTA<sup>®</sup> without talking to your doctor.

Take BREO<sup>®</sup> ELLIPTA<sup>®</sup>:

- exactly as prescribed;
- every day;
- every 24 hours, at about the same time each day

Rinse your mouth with water after each inhalation. Do not swallow the water.

If you have any difficulties or you are unsure about how or when to take BREO<sup>®</sup> ELLIPTA<sup>®</sup> check with your doctor or pharmacist.

#### **COPD Usual Adult dose:**

One inhalation through the mouth once a day.

#### **Asthma Usual Adult dose:**

One inhalation through the mouth once a day.

Your doctor will determine the dose based on the severity of your asthma and if you have liver disease.

If you have liver disease, your doctor may decide that you should use the lower strength of BREO<sup>®</sup> ELLIPTA<sup>®</sup> (100mcg/25 mcg).

Do not take more than the recommended dose.

#### **Overdose:**

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

If you accidentally take a larger dose of BREO<sup>®</sup> ELLIPTA<sup>®</sup> (i.e. more drug than recommended by your doctor), you may feel shaky, have a headache, or feel like your heart is beating faster than usual. Talk to your doctor or pharmacist right away if this occurs.

If you have taken larger doses than instructed for a long period of time, you should ask your doctor or pharmacist for advice.


#### **Missed Dose:**

If you miss a dose, carry on and take your next dose at the usual time the next day. **Do not** take an extra dose to make up for the missed one.




**About your BREO® ELLIPTA® Inhaler:**

The ELLIPTA® inhaler is packaged in a tray, with a peelable foil lid. **Do not remove the foil lid until you are ready to use the inhaler.** Peel back the lid to open the tray.



In the tray, you will find a small sachet containing a drying agent to prevent moisture from forming inside the packaging. Once you have opened the lid of the tray, throw away the sachet. It is dangerous to eat or inhale the contents of the sachet, so it should be kept away from children and pets.



**BREO® ELLIPTA® expires 6 weeks after you have opened the lid of the tray.**

The plastic ELLIPTA® inhaler has a light grey body, a pale blue mouthpiece cover, and a dose counter. The mouthpiece and the air vent are hidden by the cover and can only be seen when the cover is opened.

**Cover**

Each time you open this, you prepare one dose of medicine.

**Dose Counter**


This shows how many doses of medicine are left in the inhaler.

**Before the inhaler has been used, it shows exactly 30 doses (14 for sample and hospital packs).**

It counts down by 1 each time you open the cover.

**When fewer than 10 doses are left, half of the dose counter shows red to remind you to refill your prescription.**

**After you have inhaled the last dose, half of the dose counter shows red and the number 0 is displayed.** Your inhaler is now empty.



The ELLIPTA® inhaler is a ready-to-use device. You will not need to prime it before using it for the first time.

Please follow the instructions ‘OPEN, INHALE, and CLOSE’ to use your ELLIPTA® inhaler. The instructions shown below apply to both the 30-dose and 14-dose ELLIPTA® inhaler.


**OPEN:**

**How to activate the ELLIPTA® Inhaler for use:**

Do not shake the ELLIPTA® inhaler at any point during use as this is not necessary.

1. When you take your ELLIPTA® inhaler out of its tray it will be in the closed position.
2. Keep the cover closed until you are ready to inhale a dose.
3. When you are ready, slide the blue cover to the side until you hear a ‘click’.
4. The dose counter will now count down by one number. This shows that the dose is ready to inhale. *If the dose counter does not count down as you hear the ‘click’, the inhaler **will not deliver the medicine.** If this occurs, take it back to your pharmacist for advice.*


You are now ready to inhale a dose.



Do not block the air vent with your fingers.




4. Take one long, steady, deep breath in. Hold this breath for as long as possible (minimum 3-4 seconds).




**INHALE:**

**How to take the medication:**


1. Sit down or stand in a comfortable position.
2. While holding the inhaler away from your mouth, exhale a complete breath (i.e. breathe out as far as is comfortable). Do not breathe out into the inhaler.



3. Put the mouthpiece between your lips, and close your lips firmly around it. *Do not block the air vent with your fingers or the inhaler mouthpiece with your teeth.*



5. Remove the inhaler from your mouth.
6. Exhale slowly and gently.



7. Continue to breathe normally.
8. Rinse your mouth with water. **Do not** swallow.



You may not be able to taste or feel the medicine, even when you are using the inhaler correctly.


**How to clean the ELLIPTA® Inhaler:**

You can clean the mouthpiece of the inhaler with a clean dry tissue after you have inhaled the medicine.

**CLOSE:**

**How to close the ELLIPTA® Inhaler:**

Once you have cleaned the ELLIPTA® inhaler you should slide the cover upwards as far as it will go to cover the mouthpiece.



**IMPORTANT**

Only open the ELLIPTA® inhaler when you are ready to take a dose. **If you open and close the cover of the ELLIPTA® inhaler without inhaling the medicine, you will lose the dose. It is not possible to accidentally take extra medicine or a double dose in one inhalation.**

**When fewer than 10 doses are left, half of the dose counter shows red, to remind you to refill your prescription. After you have used the last dose, half of the dose counter shows red and the number 0 is displayed. Your inhaler is now empty. If you open the cover after this, the dose counter will change from half red to completely red.**

Discard the inhaler 6 weeks after opening the foil lid of the tray or when the dose counter on the inhaler reads “0”, whichever comes first.

Never try to alter the numbers on the counter or detach the counter on the front of the ELLIPTA® inhaler. The counter cannot be reset and is permanently attached to the inhaler.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Side effects may include:

- Itchy, runny or blocked nose (nasopharyngitis)
- Infection of the nose or throat
- Common cold
- Sore, raised patches in the mouth or throat caused by a yeast infection (*candidiasis*/ thrush). After using BREO® ELLIPTA®, rinse your mouth out with water immediately (do not swallow) as it may help stop this side effect from occurring. Cleaning dentures may also help
- Inflammation of the sinuses (sinusitis)
- Pain and irritation in the back of the mouth and throat
- Headache
- Voice disorders
- Abdominal pain
- Flu (influenza)
- Back pain
- Cough
- Nausea
- High temperature (*fever*)
- Dizziness
- Painful joints
- Hoarseness and voice changes
- Respiratory tract infection
- Anxiety
- Tremor
- Muscle spasms

**If any of these affects you severely, tell your doctor, nurse or pharmacist.**

BREO® ELLIPTA® can cause abnormal blood test results such as decreased levels of potassium and increased blood sugar. Your doctor will decide when to perform blood tests and will interpret the results.

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

Symptom / effect		Talk with your doctor or pharmacist		Stop taking drug and seek immediate medical help
		Only if severe	In all cases	
Common	<b>Thrush (yeast infection):</b> White patches in the mouth and on the tongue, sore throat		✓	
	<b>Bronchitis</b> (inflammation of the lungs).		✓	
	<b>Bone Fractures or Osteoporosis:</b> In situations where healthy people would not normally break a bone you may have sudden pain in any location and especially in the wrist, spine or hip. This may be a fracture.		✓	
	<b>COPD</b> (shortness of breath, cough, chest discomfort and coughing up mucus).		✓	
	High blood pressure, increased or irregular heart beat.		✓	
	<b>Pneumonia</b> ( <i>an infection of the lungs</i> ): Fever, chills, increase in sputum production, change in sputum colour, increased cough or an increase in breathing difficulties.		✓	
	Flu like symptoms ( <i>influenza</i> )		✓	
	<b>Decreased levels of potassium in the blood:</b> Irregular heartbeats, muscle weakness and spasms and generally feeling unwell		✓	
Uncommon	<b>Increased blood sugar:</b> Frequent urination, thirst, and hunger	✓		

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

Symptom / effect	Talk with your doctor or pharmacist		Stop taking drug and seek immediate medical help
	Only if severe	In all cases	
Rare	<b>Bronchospasm:</b> Sudden worsening of shortness of breath and wheezing right after inhaling BREO <sup>®</sup> ELLIPTA <sup>®</sup> .		✓
	<b>Allergic Reaction:</b> Skin rash, hives, redness, swelling of the face, lips, tongue or throat (angioedema), becoming very wheezy, coughing or difficulty swallowing or breathing, suddenly feeling weak or light headed (may lead to collapse or loss of consciousness).		✓
	<b>Fast heartbeat</b>		✓
	<b>Heart palpitations</b>		✓
Very Rare	<b>Decreased Adrenal Function:</b> Tiredness, weakness, nausea and vomiting, low blood pressure.		✓
Unknown	<b>Glaucoma:</b> Increased pressure in your eyes, and/or eye pain.		✓
	<b>Cataract:</b> Clouding of the lens in the eye, blurry vision, and/or eye pain.		✓
	<b>Churg-Strauss Syndrome:</b> A flu-like illness, rash, pins and needles or numbness of arms and legs, severe sinusitis and worsening lung or breathing problems.		✓

*This is not a complete list of side effects. For any unexpected effects while taking BREO<sup>®</sup> ELLIPTA<sup>®</sup>, contact your doctor or pharmacist.*

## HOW TO STORE IT

Keep out of the reach and sight of children. Your medicine may harm them.

Keep your inhaler in a cool dry place away from direct heat or sunlight. Keep it closed when not in use.

Do not store BREO<sup>®</sup> ELLIPTA<sup>®</sup> in areas above 25°C.

If you store in a refrigerator, allow the inhaler to return to room temperature for at least an hour before use.

BREO<sup>®</sup> ELLIPTA<sup>®</sup> expires 6 weeks after you have opened the lid of the tray.

## REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program  
Health Canada  
Postal Locator 0701E  
Ottawa, Ontario  
K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

*NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.*

## MORE INFORMATION

You may need to read this package insert again. **Please do not throw it away** until you have finished your medicine. This document plus the full product monograph, prepared for health professionals can be found at:

<http://www.gsk.ca> or by contacting the sponsor, GlaxoSmithKline Inc., at:  
7333 Mississauga Road  
Mississauga, Ontario  
Canada L5N 6L4  
1-800-387-7374

This leaflet was prepared by GlaxoSmithKline Inc.

Last revised: January 27, 2016

©2016 GlaxoSmithKline Inc. All Rights Reserved  
BREO and ELLIPTA are registered trade-marks of Glaxo Group Limited, used under license by GlaxoSmithKline Inc.

BREO<sup>®</sup> ELLIPTA<sup>®</sup> was developed in collaboration with Theravance Inc.